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Abstract
Abstract
Cyclin D l, a cell cycle regulator, plays an important role in cell cycle progression. As 
overexpression o f cyclin D l has been observed in various cancers, it has been 
considered that high level o f cyclin D l may cause uncontrolled cell proliferation and 
thus give rise to cancer. Interestingly, we showed that a POU transcription factor Bm- 
3b, which has been shown to contribute to uncontrolled cell growth and cause 
tumourigenesis when expressed at a high level, correlates to the level o f cyclin Dl 
mRNA—when the level o f Bm-3b mRNA increased, the levels o f cyclin D l mRNA 
increased; when the level o f Bm-3b mRNA decreased, the level o f cyclin D l mRNA 
also decreased. Thus, the strong correlation between Bm-3b and cyclin D l indicates 
that Bm-3b, at least in part, contributes to uncontrolled proliferation by regulating the 
gene expression o f cyclin D l .
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Chapter one 
Introduction
1.1 Gene expression and transcription
Gene expression is of paramount importance as it controls growth, development and the 
normal function o f a cell. Changes in gene expression may affect those events and may 
contribute to diseases (Alberts et al. 1994; Lewin 2000). Thus, understanding gene 
expression is the key to understand how a cell is regulated during various processes such as 
growth and differentiation.
Generally, gene expression involves converting genetic information (genotype) into 
corresponding characteristics (phenotype). In this process, which is also known as the 
fundamental dogma, DNA (genotype) is transcribed into RNA and RNA is translated into 
proteins which produce the corresponding characteristics (phenotype) of an individual. 
Therefore, the process o f transcription, whereby RNA products are produced from DNA, is 
an essential and crucial element in controlling gene expression (Latchman 1998).
The process of transcription is complex. In eukaryotic cells, initiation of transcription 
involves the sequential binding of general transcription factors including TF2B, D, E, F, H 
and RNA polymerase II to a specific DNA sequence called promoter (Alberts et al. 1994;
2
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Lewin 2000). Through this process, the general transcription factors regulate the rate of 
transcription initiation by either speeding up or slowing down the assembly in response to 
regulatory signals. Apart from the general transcription factors, there are other transcription 
factors regulating transcription by activating or repressing the process of transcription 
(Alberts et al. 1994). The POU transcription factor is such factor acting which regulates gene 
expression.
1.2 The POU transcription factors
The initial identification o f three mammalian transcription factors, the pituitary-specific Pit-1, 
the octamer-binding proteins Oct-1 and Oct-2, and a nematode factor Unc-86 led to the 
identification of the POU (Pit-Oct-Unc) transcription factor family (Latchman 
126-33;Andersen and Rosenfeld 2-35;Samady et al. 317-23). These four transcription factors, 
as well as other transcription factors discovered subsequently, are characterized by a unique 
DNA-binding domain which is referred as the POU domain (Andersen and Rosenfeld 
2-35;Wegner, Drolet, and Rosenfeld 488-98).
1.2.1 POU domain
The POU domain is a unique bipartite DNA-binding domain (Andersen and Rosenfeld 
2-35;Wegner, Drolet, and Rosenfeld 488-98) which consists o f approximately 150-160 amino 
acids (Latchman 126-33). Based on the sequence homology within the domain, it can be 
further subdivided into two subdomains—the POU-specific domain (POUs) and the POU 
homeodomain (P O U hd) (Figure 1.1) (Klemm et al. 1994; Wegner et al. 1993).
3
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Figure 1.1 schematic representation o f  the secondary structure elements o f  the POU domain
The POU domain can be subdivided into the highly conserved POUs domain and the P O U Hd separated by a linker 
region that varies in length (14-25 amino acids). The POUs domain consists o f  4 a-helices (cylinders) while the 
P O U hd consists o f  3 a-helices. Conserved regions o f basic amino acids are found in both the POUs and P O U hd 
(indicated by black boxes). (Adapted from Wegner et al. 1993)
1.2.1.1 The POU-specific domain (POUs)
The POUs is unique to POU transcription factors. It is a highly conserved amino-terminal 
sequence of 75-82 amino acids (Figure 1.1). This domain contains four a-helices which are
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arranged around a hydrophobic core. This subdomain provides a high affinity site specific
DNA-binding property to the POU domain. Helix 3 is responsible for DNA recognition
(Klemm et al. 1994; Wegner et al. 1993).
1.2.1.2 The POU homeodomain (POUhd)
The POUhd shows an unambiguous similarity to the DNA-binding homeodomain of various 
developmental regulators in Drosophila (Andersen & Rosenfeld 2001). It is a highly 
conserved carboxyl-terminal sequence of 60 amino acids (Figure 1.1). Similar to the classic 
homeodomain, the POUhd consists of three a-helices. The first two helices are relatively 
variable amongst the family whereas the third helix is highly conserved. The third helix is 
known as the recognition helix as it is responsible for binding the major groove of the DNA. 
Compared with the POUs, the POUhd provides a lower DNA-binding affinity and specificity 
(Klemm et al. 1994; Wegner et al. 1993).
1.2.1.3 Linker region
Apart from the POUs and POUhd> there is another protein sequence called the linker region 
within the POU domain (Figure 1.1). The linker region is less conserved amongst the family. 
This region is responsible to link the POUs and POUhd and acts as a flexible tether which 
allows the two sub-domains to bind cooperatively to the DNA (Klemm et al. 1994; Wegner et 
al. 1993).
5
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1.2.2 Family members of POU transcription factors
The POU domains are classified into six different groups based on the sequence homology of 
the linker region and the main cluster at the amino-terminus o f the P O U hd (Andersen and 
Rosenfeld 2001). Table 1.1 provides brief information about all the identified POU 
transcription factors, however, for the purpose of this thesis, only the class IV mammalian 
POU domain transcription factor, which is also known as Bm-3, will be discussed.
6
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Class Factor Chromosome
location
expression Knock out phenotype
I Pit-1 Mouse 16 Pituitary Dwarfism
II Oct-1 Mouse 1 
Human 1
Ubiquitous Not reported
Oct-2 Mouse7 
Human 19
Nervous system, 
lymphoid cell, 
testis and kidney
Aberrant B-cell 
maturation
III Bm-1 Mouse 1 CNS, Kidney Not reported
Bm-2 M ouse 4 
Human 6
CNS Defects in
differentiation/migrati 
on o f hypothalamic 
neurons
Bm-4 Mouse X CNS Defects in inner ear 
development
Tst-1 Mouse4 Nervous system, 
testis
Defective myelination
IV Brn-3a
Brn-3b
Bm-3c
Mouse 14 
Human 13
Mouse 8 
Human 4
Mouse 18 
Human 5
Nervous system, 
reproductive 
system, heart and 
lungs
Nervous system, 
reproductive 
system and heart
Nervous system,
reproductive
system
Lack o f  specific 
sensory and autonomic 
neurons, non-viable
Loss o f  retinal 
ganglian cells, blind
Loss o f  inner ear cells, 
D eaf
V Oct3/4 Mouse 17 
Human 6
Testis, ovaries, 
germ cells, ES 
cells
All cells in the early 
embryo become 
trophoblasts
VI Brn-5 Mouse 15 
Human 12
Nervous system, 
skeletal muscle, 
heart, lung
Not reported
Table 1.1 The six classes o f  POU transcription factors. The chromosome location in both mouse and humans 
and expression pattern is indicated. The phenotype o f  the knock out mouse models, where known, is also briefly 
discussed. (CNS-central nervous system, ES-embryonic stem cell). (Adapted from Andersen and Rosenfeld 
2001).
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1.2.2.1 Class IV/Brn-3
Three different proteins have been identified in this group; they are Bm-3a (Bm-3.0), Bm-3b 
(Bm-3.2) and Bm-3c (Bm-3.1). These members are expressed in both the central and 
peripheral nervous systems where they regulate neuronal growth and differentiation 
(Budhram Mahadeo et al. 1996;Milton et al. 1995).
The transcription factors belonging to this group have a short homologous region at the 
N-terminal and a highly conserved POU domain at the C-terminal o f the protein. This short 
sequence within the N-terminal, which contains about 40 amino acids, is referred as the POU 
IV box (Figure 1.2)(Samady et al. 317-23;Gerrero et al. 10841-45). The POU IV box and the 
POU domain are the activation domains of the transcription factor and are able to act on 
different promoters to regulate transcription (Smith et al. 460-70;Smith et al. 4100-07). A 
detailed discussion of all three members would be out of the scope of this thesis. For the 
purpose o f the thesis, only Bm-3b is discussed.
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Figure 1.2 Schematic representation o f  the Bm-3a and Bm-3b transcription factors and their two isoforms. The 
long isoform [Bm-3a(l) and Bm-3b(l)] o f  both transcription factors contain an extra N-terminal domain that 
contains a highly conserved region, the POU IV box. The highly conserved POU IV box is only found in the long 
isoforms o f  both proteins while the POU domain is found in both long and short isoforms o f each protein.
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1.3 The Brn-3b transcription factor
Introduction
Bm-3b was first detected in ND7 cells using degenerative oligonucleotides to amplify 
by novel primers (Lillycrop et al. 1992). It has been found to play a role in neuronal 
growth and differentiation. The expression of Bm-3b induces cell proliferation and 
represses cell differentiation (Latchman 1999).
Structurally, there are two forms o f Bm-3b, the shorter 30kDa form referred as Bm-3b 
short form (Bm-3b(s)) whereas the longer form is 43-46kDa and is called Bm-3b long 
form (Bm-3b(l)) (Latchman 1999;Xiang et al. 1993). The expression o f the Bm-3b(s) 
and Bm-3b(l) are the results o f the alternate splicing o f the Bm-3b RNA.
1.3.1 Alternative splicing of Brn-3b
Bm-3b is encoded by a gene located at chromosome 4 (4q31.2) in human cells (Xiang 
et al. 689-701). The gene contains 2 exons spanning approximately 4 kb o f genomic 
DNA, and is subject to alternative splicing. When the Bm-3b gene is transcribed from 
a downstream promoter, mRNA is produced which in turn is translated to Bm-3b(s).
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The Bm-3b(s) does not have the POU 4 box. However, when the gene is transcribed 
from an upstream promoter, a long mRNA with an additional exon is produced. 
Following translation, Bm-3b(l), which is a 410-amino acid polypeptide consisting of 
an additional N-terminal sequence, is produced (Dennis et al. 2001;Theil et al. 
1993;Xiang et al. 1993).
1.3.2 Function of Brn-3b
Bm-3b has been showed to play a critical role in cell proliferation and differentiation 
(Budhram-Mahadeo et al. 1994). High levels of Bm-3b promotes proliferation and 
represses differentiation. As a result, overexpression o f it promotes the maintenance 
o f the non-differentiated proliferative phenotype of reduced process outgrowth, which 
is a normal response o f differentiation. However, this inhibitory effect ceases by 
decreasing the expression level o f Bm-3b (Smith et al. 1997).
As a transcription factor, Bm-3b regulates cell proliferation and differentiation by 
transcriptional regulation. It promotes proliferation by upregulating expression o f 
specific target genes involved in the cell cycle including CDK4 and cyclin D l
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(Samady et al. 2004) and by downregulating expression o f a tumour suppressor gene, 
BRCA-1 (Dennis et al. 2001). On the contray, it represses differentiation by 
downregulating the expression o f certain genes which are responsible for 
differentiation such as SNAP-25 (Lakin et al. 1995), neurofilament (Smith et al. 1997) 
and a-intemexin (Budhram-Mahadeo et al. 1995). Bm-3b appears to regulate cell 
proliferation, therefore high level o f Bm-3b expression may cause uncontrolled cell 
proliferation, which is one o f the characteristics of cancer cells.
1.4 Brn-3b and cancer
Bm-3b is highly expressed in various cancer cell lines, including neuroblastoma and 
breast cancer cell lines (Dennis et al. 2001; Irshad et al. 2004;Sonia et al. 2005). As 
well as increasing cell proliferation, Bm-3b also promotes the invasiveness and drug 
resistance o f cancer cells (Irshad et al. 2004;Sonia et al. 2005). In this section, the 
basic concepts o f cancer and the possible roles for Bm-3b in cancer cells are 
discussed.
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1.4.1 Definition of cancer
Introduction
Cancer refers to diseases that exhibit two main characteristics that enable them to 
develop and spread: (1) uncontrolled cell growth in the absence o f mitogenic stimulus 
and (2) the ability to metastasize to normal tissues either locally or at distant sites in 
the body. Indeed, it is the combination of these features which makes cancer 
dangerous. When the proliferation o f cells is out o f control, it will give rise to a 
tumour. However, if  the cells in the tumour cluster together to form a single mass, the 
tumour is said to be benign as a complete cure can be achieved by surgically removal 
of the mass. A tumour is classified as a cancer when the uncontrolled proliferating 
cells have the ability to spread and invade other tissues to form secondary tumours. 
This type o f tumour is called a malignant tumour (Alberts et al. 1994).
1.4.2 Types of cancer
The human cancers arising from the epithelium (the layers o f cells covering the body's 
surface and lining internal organs and various glands) are called carcinomas. Cancers
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occur in the supporting tissues o f the body, such as bone, muscle and blood vessels 
are called sarcomas(Alberts et al. 1994). Cancers derived from immature progenitor 
blast cells are called neuroblastoma (Noesel and Versteeg 2004). Cancers of the blood 
and the lymph glands are called leukemias and lymphomas, respectively (Alberts et al. 
1994).
1.4.3 The causes of cancer
The formation o f cancer is complex; it can be caused by various factors such as 
exposure to chemical carcinogens, ionizing radiation, virus and alteration o f cellular 
internal signals. However, in principle, it is caused by the alteration o f genetic 
material (mutation) due to the factors mentioned. As a result o f the mutation, the gene 
expression pattern changes and this causes cells to alter their size, shape, surface 
characteristics and behavior. The cells are transformed so that they grow indefinitely 
and become independent o f certain growth factors which are required for normal cell 
growth. Finally, the cells spread and invade normal tissue to establish a new colony 
(Alberts et al. 1994;Lewin 2000).
14
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1.4.4 Metastasis of cancer cells
Introduction
The process of the cancer cells migration is called metastasis. In this process, the cells 
o f a solid tumour loosen their adhesion at original site, escape from the tissue origin 
and burrow through other tissues so that they can reach the circulatory system. In the 
circulatory system, they can migrate to distant sites. After traveling to a new organ, 
the cancer cells burrow out o f the blood or lymph vessels and invade the surrounding 
tissues. There they continue to multiply, forming secondary tumours. Eventually, 
these tumours disrupt the body's normal functions and often lead to death (Alberts et 
al. 1994).
1.4.5 Brn-3b and various cancer cell lines
The whole process o f transformation and metastasis is a result o f change of normal 
gene expression (Lewin 2000). Therefore, transcription, which is an essential element 
o f gene expression, plays an important role in cancer formation. Indeed, 
overexpression o f Bm-3b, which has been observed in various cancer cells including
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neuroblastoma and breast cancer cell lines, has been shown to be related to 
tumourigenesis (Dennis et al. 2001;Irshad et al. 2004).
1.4.6 Brn-3b and neuroblastoma
Bm-3b is expressed at high levels in various neuroblastoma cell lines and human 
neuroblastoma tumours. It was shown that an increase o f the level o f Bm-3b enhances 
cell growth and proliferation. Moreover, overexpression o f Bm-3b increases the 
invasiveness and tumor formation ability of neuroblastoma cells whereas reduction of 
the Bm-3b expression decreases the invasiveness and tumor formation ability of 
neuroblastoma cells. These findings indicate that Bm-3b is a potent enhancer of 
tumourigenesis (Irshad et al. 2004).
Bm-3b exerts the effect o f tumourigenesis by regulating its target genes. It has been
observed that Bm-3b stimulates the expression o f neuronal nicotinic acetyl choline
receptor alpha II gene (Milton et al. 1995) and the synapsin I (Smith et al. 1997)
which are responsible for cell proliferation whereas it represses the expression of
SNAP-25 (Lakin et al. 1995), neurofilament (Smith et al. 1997) and a-intemexin
16
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(Budhram-Mahadeo et al. 1995) which are responsible for differentiation. Therefore, 
increased expression of Bm-3b enhances the target genes that are responsible for 
proliferation and inhibits the target genes that are responsible for differentiation.
1.4.7 Brn-3b and breast cancer
Apart from neuroblastoma cells, Bm-3b is expressed at a high level in MCF7 human 
breast adenocarcinoma cells and a number of human breast tumor samples compared 
to the level in normal mammary epithelium (Samady et al. 317-23;Budhram-Mahadeo 
et al. 6684-91). It has been shown that Bm-3b promotes cell growth and proliferation 
through its ability to inhibit the expression of the tumour suppressor gene BRCA-1 
and through its interaction with the estrogen receptors ((Samady et al. 
317-23;Budhram-Mahadeo et al. 6684-91).
BRCA-1 gene is associated with numerous cell functions, including cell cycle control, 
controlling protein degradation, DNA damage repair, and transcriptional (gene 
activity) regulation (Kenemans et al. 2004). Mutation o f BRCA-1 has been found in 
45% o f hereditary breast cancer patients (Dennis et al. 2001). Though there is no 
evidence o f mutation o f the BRCA-1 gene in sporadic breast cancer, it has been
17
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observed that in invasive breast cancer BRCA-1 expression is decreased compared to 
normal mammary epithelial tissue. Therefore, repression o f the BRCA-1 expression 
leads to enhanced risk o f tumor formation (Dennis et al. 2001;Kenemans et al. 2004).
The estrogen receptor (ER) plays a role in breast cancer progression. It activates 
proliferation by binding to its responsive element such as the vitillogenenin promotor.
To bind to a promoter, indeed ER needs to interact with an accessory protein. It has 
been shown that Bm-3b has the ability to interact the ER via a protein-protein 
interaction (Budhram-Mahadeo, Parker, and Latchman 1029-41;Samady et al. 
317-23)).
1.5 Brn-3b and Cell cycle
One of the important aspects o f Bm-3b in cancer is that it promotes proliferation 
(Irshad et al. 2004;Sonia et al. 2005). Previous studies have shown that Bm-3b plays 
an important role in regulating proliferation by upregulating expression of factors 
related to cell cycle progression (Samady et al. 2004). In this section, the basic 
concept of the cell cycle is described. Also, the role o f bm-3b in the cell cycle is 
discussed.
18
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1.5.1 Overview of the Cell cycle
The cell cycle consists o f several clearly defined phases: G l, S, G2 and M. G1 phase 
is a gap phase during which the cell prepares for DNA replication. In this phase, the 
cell makes the decision to proceed, pause, or exit the cell cycle based on the 
mitogenic and growth inhibitory signals. S phase is a phase when DNA synthesis and 
chromosome duplication occurs. G2 phase is a phase that cell prepare for cell division. 
M phase is the phase that chromosomes a re segregated into separate nuclei and 
cytokinesis occurs to form two daughter cells. If the cells do not continuously divide, 
there is an additional resting stage termed GO phase between phases M and Gl 
(Figure 1.3) (Johnson and Walker 1999; Stacey 2003).
19
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The Cell Cycle
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Fig. 1.3 The basic morphology o f  cell cycle.
1.5.1.1 Cyclin-dependent kinases
The transition from one cell cycle phase to another occurs in an orderly fashion and is 
regulated by different cellular proteins. Key regulatory proteins are the 
cyclin-dependent kinases (CDKs), a family of serine/threonine protein kinases that are 
activated at specific points o f the cell cycle. There are four CDKs being active during 
the cell cycle, they are CDK4, CDK6 (active during G l phase), CDK2 (active during 
G l and S phase) and CDK1 (cdc2) (active during the G2 and M phase). When 
activated, CDK induce downstream processes by phosphorylating selected proteins. 
CDK protein levels remain stable during the cell cycle, in contrast to their activating
20
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proteins, the cyclins (Arellano and Moreno 1997;Swanton 2004;Vermeulen et al. 
2003).
1.5.1.2 Cyclins
Cyclins are the target substrates o f the CDKs. They bind to CDKs and control the 
ability o f the CDKs to phosphorylate their target proteins (Vermeulen et al. 2003). 
During the cell cycle progression, the levels of cyclins oscillate due to periodic 
synthesis and degradation (Fig. 1.4). In this way, cyclins can control the activation of 
the CDKs in different phases (Arellano and Moreno 1997;Swanton 2004;Vermeulen 
et al. 2003).
In mammalian cells, the cell cycle starts progressing through G l phase when CDK4 
or CDK6 associats with the D-type cyclins (cyclins D l, D2 and D3). Cyclin E is 
expressed in late G l, the formation of CDK2/cyclin E complexes is required for Gl to 
S transition (Ohtsubo et al. 1995;Resnitzky et al. 1994) and initiation o f DNA 
synthesis (Jackson et al. 1995;Krude et al. 1997;Ohtsubo et al. 1995). After activation
21
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by cyclin E, CDK2 is subsequently activated by the A-type cyclins (cyclin A l and A2) 
during S phase and this complex is required for the progression through S phase. The 
activation o f CDK1 or ddc 2 by cyclin B triggers transition from G2 to M (Jeong et al. 
2003;Elledge 1996).
Cyclin regulation during 
cell cycle progression
M ito g « n s tim  U a tio n
Figure 1.4 The relative amount o f  cyclins in different phase. A refers to cyclin A, B refers to cyclin B, 
D refers to cyclin D and E refers to cyclin E.
1.5.2 The G l/S  transition
G l/S  transition is important in regulating cell growth and proliferation. As mentioned,
cyclin D l, CDK4, cyclin E and CDK2 are responsible for the transition. In mid Gl
22
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phase, CDK4 which associates with Cyclin D1 phosphorylates a protein called 
retinoblastoma protein (RB). Before the phosphorylation, the hypophosporylated RB 
inhibits cell cycle progression by binding to a transcription factor E2F which regulates 
the expression o f many genes that encodes proteins involved in cell cycle progression 
and DNA synthesis. The phosphorylation of RB causes it to release the E2F, and 
therefore the E2F becomes functionally activated and can regulate gene expression o f 
various genes such as cyclin E, CDK2, dihydrofolate reductase, thymidine kinase and 
DNA polymerase a. As a result, cyclin E and CDK2 are expressed and they associate 
together to drive the cell to progress from late Gl into S phase. The cyclin E/CDK2 
complex maintains the hyperphosphorylated state of the RB, thus they take part in a 
positive feedback loop for accumulation of active E2F (Johnson and Walker 1999; 
Resnitzky et al. 1994;Stacey 2003).
The G l/S  transition is an important cell cycle checkpoint. In the G l phase, the cell is 
preparing itself for DNA synthesis. G l arrest has been observed when the cell is 
subjected to DNA damage. The arrest prevents the cells from uncontrolled growth. 
However, overexpression o f cyclin D1 and E, which have been observed in various 
cancer cells, prevents the cell cycle arrest (Resnitzky et al. 1994;Noesel and Versteeg 
2003).
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1.5.3 Relationship between brn>3b, cyclin D1 and CDK4
Introduction
It has been observed that CDK4 and cyclin D1 are target genes o f Bm-3b. An increase 
in Bm-3b expression correlated to an increase of the CDK4 and cyclin D1 expression 
level. Interestingly, both the Bm-3b(s) and Bm-3b(l) can activate CDK4 expression, 
this indicates that it is the POU domain of Bm-3b that acts as a transcriptional 
activation domain (Samady et al. 317-23).
Cyclin D1 and CDK4 play a critical role in tumourigenesis. Indeed, overexpression of 
both cyclin D1 and CDK4 has been shown to relate to some human tumors (Samady 
et al. 317-23;Zhang et al. 169-75). Moreover, their overexpression o f them prevents 
growth arrest and results in the immortalization o f primary cells (Samady et al. 
317-23;Holland et al. 3644-49). As Bm-3b is an upstream regulator o f both the cyclin 
D1 and CDK4, high level o f Bm-3b expression, which has been observed in various 
cancer cells, increases the expression of these two genes and thus induces 
tumourigenesis.
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1.6 Objectives of the study
Introduction
Alteration o f normal cell cycle progression has been shown to be implicated in cancer 
formation. It has been shown that deregulated high expression o f cyclin D1 directly 
contributes to tumourigensis. As Bm-3b plays a role in regulating the expression of 
cyclin D l, thus Bm-3b is responsible, as least in part, at initiating tumourigenesis 
through this pathway. However, the expression pattern of Bm-3b in different phases 
of the cell cycle and when it activates its target gene cyclin D l remain to be 
elucidated. Therefore, this study aims to find out the expression pattern of Bm-3b at 
different phases o f the cell cycle and when it activates its target gene cyclin D l (refer 
to section 2.2 for experimental set up).
Another aim o f this study is to discover the factor which causes the level of Bm-3b to 
increase in cancer cells. Exposure to carcinogens is a know cause o f cancer. It has 
been shown that exposure to benzo(a)pyrene increases the risk to have cancer (Davis 
et al. 2002). As Bm-3b is also highly expressed in cancer cells lines and regulates 
various genes which cause tumourigenesis, it may be possible that exposure to 
benzo(a)pyrene may increase the expression o f Bm-3b which leads to tumourigenesis. 
Therefore, an experiment was carried out to investigate whether the expression of
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Bm-3b changed when the cells were exposed to benzo(a)pyrene (refer to section 2.2 
for experimental set up).
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Chapter Two
Materials and Methods
Various methods were carried in this study. They are methods related to cell culture 
(section 2.1), setting up the experiments in this study (section2.2), fluorescence 
activated cell sorting (FACS) analysis (section 2.3), quantitative reverse transcriptase 
polymerase chain reaction (qRT-PCR) (section 2.4) and western blotting (section 
2.5).The details of those methods are described in this chapter.
2.1 Cell culture
Cell culture is a very important and invaluable tool for biological investigation. It 
allows analysis o f biological properties and processes that are not readily assessable at 
the level o f the intact organism (Helgason & Miller 2005). Therefore, it is important 
to master the cell culture techniques before starting any experiment.
In this section, the cell lines used in the experiments, ND7 and MCF7, are discussed.
Moreover, the procedures for culturing, passaging, thawing, cryopreservation,
determination of cell numbers and viability are described. It should be stressed that all
materials used were sterilized and all the procedures were performed in a laminar
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flow hood, which provides a sterile environment. All the reagents were warmed up to 
37 °C before use. The surface of all the flasks and bottles were decontaminated with 
70% alcohol before taking into a laminar flow hood. Gloves and laboratory coat were 
always worn. 70% alcohol was sprayed on the gloves to decontaminate every time 
before working in the hood.
2.1.1 Cell lines
ND7 cells were hybrid cells made by fusing the N18 TG2 azaguanine-resistant 
neuroblastoma and the primary sensory neurons of the rat dorsal root ganglion (Wood 
et al. 1990). This allows the cells to bear the characteristics o f immortalization and 
sensory neurons(Lillycrop et al. 1992;Suburo et al. 1992;Wood et al. 1990). Moreover, 
the cells can be induced to differentiate to non-dividing and process-bearing cells with 
the characteristics o f mature sensory neurons under various treatments(Lillycrop et al. 
1992;Suburo et al. 1992).
MCF7 cells were breast cancer line obtained from American Type Culture Collection 
(Manassas, VA). MCF7 cells are epithelial-like human breast adenocarcinoma derived 
from pleural effusion. The cells are highly rearranged, where translocations occur in
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all chromosomes except chromsome 4(Promochem 2005).
2.2 Basic cell culture techniques
ND7 and MCF7 cells were cultured in complete Liebovitz medium (L I5) (refer as full 
growth medium for ND7 cells)(Gibco) (Table 2.1) (see appendix 1 for the preparation) 
and complete Dulbeco’s Modified Eagles medium (D-MEM) (refer as full growth 
medium for MCF7 cells)(Gibco) (Table 2.2) (see appendix 2 for the preparation) 
respectively at 37°C in humidified atmosphere in 5% carbon dioxide. The cells were
periodically monitored and passaged when they reached 80%-90% confluency.
Ingredients of the completed LI 5: Proportion:
L15 IX
Fetal calf serum (gold) 10%
D-Glucose (Sigma) 1%
Sodium bicarbonate (Gibco) 4.8%
L-Glutamine (Gibco) 0.2mM
100 U/ml penicillin and 100 pg/ml 
streptomycin (P/S) (Gibco)
1%
Table 2.1 The components and their concentrations required for making com plete L I5 culture medium
for ND7.
29
Chapter 2 Materials and Methods
Ingredients o f the completed LI 5: Proportion:
D-MEM IX
Fetal calf serum 10%
100 U/ml penicillin and 100 pg/ml 
streptomycin (P/S) (Gibco)
1%
Table 2.2 The components and their concentrations required for making a com plete D-MEM culture 
medium for MCF7.
2.2.1 Cell passaging
Regular cell passage is necessary to maintain viable cells. This ensures that there are 
sufficient nutrients in the medium for cell growth and that the pH o f the medium is 
not too acidic as a result o f large amounts of cellular waste (Helgason & Miller 2005). 
The cell passage procedures for ND7 and MCF7 are slightly different, and are 
described below.
2.1.1.1 Cell passaging for ND7
ND7 cells were split when they reached 80%-90% confluency. Firstly, the flask was
hit by hand on the side where the cells attached so that the cells would detach from
the flask. The flask was then put under a light microscope to observe whether all the
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cells were detached. If not the flask would be hit again until all the cells came off. 
One tenth of the cells were seeded to a new flask. This means, for example, 2ml o f the 
cells were taken out from 20ml o f the cells and were seeded into a new flask. Full 
growth medium (Complete L I5) were added so as to fill the flask up to its suggested 
optimum volume.
2.1.1.2 Cell passaging for MCF7
MCF7 cells were split when they reached 80%-90% confluency. To start with, the 
culture medium was removed from the cells. The cells were washed twice with 
Hank’s Balanced Slat Solution (HBBS) (Gibco). Trypsin/EDTA (Gibco) was added to 
the flask after HBBS was removed. The volume of trypsin added depends on the size 
o f the flask. Usually, 3ml o f trypsin were added to a 175cm2 culture flask while 2ml 
of trypsin were added to a 125cm2 culture flask. The aim is to allow the trypsin to 
cover the whole surface o f the flask where the cells are attached. The flask was then 
hit by hand on the side where the cells are attached so that the cells would detach 
from the flask. Whether all the cells were detached was checked under a light 
microscope. If not the flask would be hit again until all the cells came off. Afterwards, 
the cells were transferred to a centrifugation tube and were pelleted at 1000 r.p.m. at
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room temperature for 5 minutes. The supernatant was removed and the pellet was 
resuspended in full growth medium (completed D-MEM). One fourth o f the cells 
were split to a culture flask. Completed D-MEM was added to fill up the flask to its 
suggested optimum volume.
2.1.2 Cryopreservation
Continuous cell culture increases the chances of cell contamination by bacteria and 
other unwanted organisms. Moreover, continuous cell culture can lead to the 
accumulation o f karyotype altemations(Helgason & Miller 2005). Therefore, in order 
to prevent loss of the cell line, it is advisable to cryopreserve some o f the cells for 
future use. The cryopreservation processes of ND7 and MCF7 cells are described in 
this section.
2.1.2.1 Cryopreservation of ND7 cells
To start with, the cells were detached from the flask. The procedures o f it are same as 
for passaging cells (please refer to section 2.1.1.1) except all the cells were transferred 
to a centrifugation tube and were pelleted at 1000 r.p.m. at room temperature for 5
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minutes. The supernatant was removed and the pellet was resuspended in the 1 ml of 
5% Dimethyl sulfoxide (DMSO) (Sigma) in FBS. The cells were transferred to a vial 
and were stored in -80 °C freezer inside an isopropanol rack overnight. The cells were 
then transferred to liquid nitrogen for long term storage.
2.1.2.2 Cryopreservation of MCF7 cells
To start with, the cells were detached from the flask. The procedures o f it are same as 
for passaging cells (please refer to section 2.1.1.2) except that the pellet was 
resuspended in 1ml o f 5% DMSO in FBS. The cells were transferred to a vial and 
were stored in -80 °C freezer inside an isopropanol rack overnight. The cells were then 
stored in liquid nitrogen the day after.
2.1.4 Thawing cells
Cell thawing is an important procedure to recover cells for experimental use. 
Improper thawing leads to unwanted cell damage or even death (Helgason & Miller 
2005). The procedure o f cell thawing of ND7 and MCF7 is the same, and is described 
in this section.
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To thaw cells, firstly, the vial containing the cells was taken out from the liquid 
nitrogen and was put into a water bath set at 37°C for 5 minutes. The cells were then 
transferred to a centrifugation tube and the 9 ml of required medium (complete L I5 
for ND7 and completed D-MEM for MCF7) was added slowly to prevent sudden 
dilution o f DMSO which can cause severe osmotic damage to the cells (Helgason & 
Miller 2005). The cells were pelleted at 1000 r.p.m. at room temperature for 5 minutes. 
The supernatant was removed and the pellet was resuspended in the required medium 
so as to remove the DMSO which is toxic to the cells. The cells were then transferred 
to a culture flask and the required medium was added to fill up the flask to its 
suggested optimum volume. The cells were cultured at 37°C in humidified 
atmosphere in 5% carbon dioxide.
2.1.5 Cell number determination
Every cell line has its own optimal density for maintaining growth and viability 
(Helgason & Miller 2005). As these factors affect the experimental settings, it is 
therefore important to determine the cell number and cell viability before carrying out 
experiments. The processes o f cell number determination for both ND7 and MCF7
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cells are the same, and are described in this section.
This first step is to detach the cells from the culture flask. This step is same as that in 
cell passaging (please refer to section 2.1.1.1 for ND7 and section 2.1.1.2 for MCF7). 
Once the cells were detached, the flask was swirled so that the cells in the flask were 
evenly distributed. lOOpl o f the cell suspension was taken out and transferred to the 
two chambers of a hematocytometer covered with a cover slip. The cell number was 
counted under a light microscope. In one chamber, there are nine 1 mm2 squares. The 
cell numbers were counted from ten of the 1 mm squares from both chambers and 
average was taken. The cell number in every ml equals to the average value of 104.
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2.2 Setting up experiments
Materials and Methods
Generally, there were three different sets of experiments in this study. The first set was 
the experiment on cell cycle arrest o f ND7 and MCF7 cells following various 
treatments to analysis mRNA levels o f Bm-3b and cyclin D l. The second set was the 
experiment of synchronization o f ND7 cells to analyze for Bm-3b and cyclin D l 
mRNA levels. The third set was the experiment on Benzo(a)pyrene exposure to ND7 
cells to analyze for Bm-3b and mRNA levels. The details o f setting up the 
experiments are described in this section.
2.2.1 The experiment on cell cycle arrest of ND7 and MCF7 cells following 
various treatments
In this experiment, 1X106 ND7 and 2X106MCF7 cells were firstly seeded on 64cm2 
petri dishes. Drugs were added after 24 hours of seeding. Five cell cycle arresting 
drugs were used. They were 5-flurouracil, hydroxyurea, colchicine, doxorubicin and 
etoposide and are described below. All the cells were harvested 12 hours after addition 
o f drugs for FACS analysis, quantitative RT-PCR and western blotting. The details of 
the whole experiment are described in this section.
Chapter 2
2.2.1.1 Treatments
Materials and Methods
5-fluorouracil
5-fluorouracil (5-FU) is an antimetabolites which induces G l or G l/S  cell cycle arrest 
in cancer cells (Johnson and Walker 1999). However, the exact molecular actions of 
these anticancer drugs on cell cycle regulation have not been fully explained yet.
Hydroxyurea
Hydroxyurea (HU) induces cell cycle arrest at the G l and S phases. This is achieved 
by its specific action on ribonucleotide reductase. Ribonucleotides are reduced by 
ribonucleotide reductase to deoxyribonucleotides; this reduction reaction is impeded 
by HU, which limits DNA biosynthesis (Yarbro 1992).
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Colchicine
Colchicine (Col) is an antimitotic agent. It induces cell cycle arrest in M phase by 
disrupting microtubules through binding to tubulin. This prevents tubulin from 
undergoing polymerization during M phase and hence causes M phase arrest (Wilson 
et al. 1999).
Doxorubicin
Doxorubicin (Dox) induces cell arrest in G2/M phase (Ling et al. 1996). It intercalates 
into DNA, blocking both the replication and transcription of the DNA (Katzung 1989). 
Moreover, it inhibits topoisomerase II activity by occupying space which is normally 
inhabited by base pairs in DNA. This process could adversely affect the formation of 
the DNA-topoisomerase II complex and the function o f this enzyme leading to 
alternation o f the DNA topology and consequently interference with the global 
structure in chromation (Foye 1995).
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Etoposide
Etoposide (Etop) induces cell cycle arrest in late S and G2 phase. Etoposide causes 
DNA damage through inhibition o f topoisomerase II and activates oxidation-reduction 
reactions to produce derivatives that bind directly to DNA. Topoisomerase II carries 
out breakage and reunion reactions o f DNA which are necessary for normal cellular 
function. (Kaufmann 1998).
2.2.1.2 Cell seeding
Cells were seeded on a 64cm2 petri dish (Falcon). The amount o f  cells seeded on the 
dish depends on the cell type and how long the experiment would last. For this 
experiment, 1X106 ND7 cells were seeded in a dish whereas 2X106 MCF7 were 
seeded in one dish. More MCF7 cells have to be seeded because MCF7 cells have a 
longer doubling time. In order to seed the correct number o f cells, the number of the 
cells was first counted (please refer to section 2.1.5). The correct number o f cells were 
then transferred to the dish and full growth medium (complete L I5 for ND7 and 
complete D-MEM for MCF7) was then added respectively to make the total volume 
up to 10 ml. The cells were incubated at 37°C in humidified atmosphere in 5% carbon
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dioxide. For each treatment, 3 petri dishes of cells were seeded for FACS analysis, 
RT-PCR and western blotting. This experiment was carried out in triplicate.
2.2.1.3 Addition of drugs
The concentration o f each drug is shown in Table 2.3. The drugs were prepared in a 
specific stock concentration so that a specific amount o f drugs were added to each 
Petri dish which contained 10 ml o f medium.
Molar
mass
Target
concentration/Final
concentration
Stock
concentration
Solvent Volume 
added to 
each dish
5-Fluorouracil 130.1 l&2.5pg/ml lmg/ml PBS 10&25pl
Hydroxyurea 76.05 l&lOmM 1M h 2o lO&lOOpl
Colchicine 399.4 lpM ImM DMSO lOjLXl
Doxorubicin 580 lpM ImM PBS 10 pi
Etoposide 588.56 lOpM lOmM DMSO lOpl
Table 2.3 The five drugs used in this study. The drugs were prepared in a stock concentration and were 
added to Petri dishes containing 10ml o f  full growth medium so as to achieve the target concentration. 
According to manufacturer’s instructions, different solvents were used to dissolve different drugs.
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2.2.1.3.1 Preparation of drugs
Materials and Methods
Generally, the drugs, which were in powder form, were weight with an electrical 
balance. Their respective solvents were added so as to make them into their respective 
stock concentration. The amount o f the solvent should be added was calculated by the 
following formula:
The amount of solvent added = (Mass/Molar mass)/Stock concentration
2.2.1.4 Controls of the experiment
For the experiment, two controls were used. One of the controls was the untreated 
cells whereas the other one was cells treated with lOpl o f DMSO as DMSO, which 
may be toxic to the cell, was used as a solvent for some o f the drugs.
2.2.1.5 Harvesting cells
All the cells were harvested after 12 hours of drugs addition/24 hours after full growth 
medium for FACS analysis, qRT-PCR and western blotting.
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2.2.2 Study on synchronization of ND7 cells
Materials and Methods
This experiment aimed to synchronize ND7 cells in G l phase o f the cell cycle by 
transferring the cells in serum free medium (see appendix 4 for preparation) for an 
optimum period o f time (see section 2.2.2.1). After the synchronization, the cells were 
transferred back to full growth medium (complete L-15) containing 20% FCS so that 
the cells resume cycling in the cell cycle (Budhram-Mahadeo et al. 1994). The cells 
were harvested at 3, 6, 12, 24, 36 and 48 hours of being transferred back to the full 
growth medium containing 20% FCS. Similar to the set one experiment, 3 Petri dishes 
were prepared for one treatment so that samples could be prepared for FACS analysis, 
qRT-PCR and western blotting. This experiment was carried out in triplicate.
2.2.2.1 Optimization of the time period for cell growth in serum free medium
An initial experiment was carried out on ND7 to determine the optimum period of 
time for serum free exposure as not all the cells will undergo cell cycle arrest if the 
exposure time in serum free medium is too short whereas if  the exposure time of cells 
in serum free medium is too long, increased cell death would occur so that fewer cells 
will be available for analysis.
Chapter 2 Materials and Methods
Six sets o f cells were grown; they were cells grown in full growth medium and serum 
free medium for 24, 48 and 72 hours. The first step of the experiment was to seed 
cells in 64cm2 Petri dishes (please see also section 2.2.1.2). After 12 hours of seeding, 
the full growth medium was removed and serum free medium was added to cells. 
Cells were harvested at different time points; the untreated cells were harvested at 24,
48, 72 hours after seeding whereas the cells grown in serum free medium were 
harvested after 24, 48 and 72 hours after addition of serum free medium. Samples 
were prepared for FACS analysis and qRT-PCR. The results o f the optimization 
showed that 48 hours o f serum free exposure was the best period o f time for 
subsequent experiments.
2.2.2.2 Addition of full growth medium containing 20% FCS to ND7 cells after 48 
hours of serum starvation of the ND7 cells
In this experiment, ND7 cells were cultured in serum free medium for 48 hours before 
full growth medium containing 20% FCS was added back to the cells. The cells were 
harvested at 3, 6, 12, 24, 36 and 48 hours after the addition o f 20% serum medium. 
This experiment was done in triplicate and samples were prepared for FACS analysis 
and qRT-PCR.
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The first step o f the experiment was to seed cells in Petri dishes (please see also 
section 2.2.1.2). After 12 hours o f seeding, all the cells were transferred to serum free 
medium except the untreated control. The full growth medium containing 20% FCS 
was added to all the cells except the 48 hours serum free control. This was done by 
removing the serum free medium and addition of 10ml o f full growth medium 
containing 20% FCS to each dish. The cells were harvested at 3, 6, 12, 24, 36 and 48 
hours after addition o f the full growth medium containing 20% FCS.
2.2.2.3 The controls
Two controls were used in the experiment; they were untreated cells for 48 hours and 
cells grown in serum free medium for 48 hours. The untreated cells were harvested 
after 48 hours o f seeding whereas the cells growth in serum free medium were 
harvested 48 hours after addition o f the full growth medium containing 20% FCS.
2.2.3 Benzo(a)pyrene exposure to ND7 cells
In this experiment, different concentrations of benzo(a)pyrene were added to ND7 
cells to investigate the effect o f this carcinogen on Bm-3b mRNA level and cell cycle
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progression.
Benzo(a)pyrene is carcinogenic and is a polycyclic aromatic hydrocarbons which 
forms by incomplete combustion. Therefore, it is abundant in the environment. When 
it is metabolically activated to form benzo(a)pyrene 7,8-diol 9,10 epoxide, it reacts 
mainly with the N2 position o f guanine and to a lesser extent with N6 position of 
adenine to form covalent adduct (Davis et al. 2002).
The first step o f the experiment was to set up the experiment was to seed cells on Petri 
dishes (please see also section 2.2.1.2). The dishes included two controls and three 
different concentrations of benzo(a)pyrene treatments. The two controls were 
untreated cells and cells treated with 10pl acetone, which was used as the solvent for 
benzo(a)pyrene. The three concentrations of benzo(a)pyrene used were 2.5pg/ml, 
5pg/ml and lOpg/ml. The cells were harvested after 12 hours o f addition of 
benzo(a)pyrene.
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2.3 Methods related to FACS analysis
Materials and Methods
2.3.1 Introduction to FACS analysis
Fluorescence activated cell sorting (FACS) machine can separate, classify and 
quantify living cells in a suspension on the basis o f size and the color of their 
fluorescence (Kimball 2003). In principle, cells suspension was passed through a 
narrow dropping nozzle so that each cell is in a small droplet. One or more laser 
beams are passed through the cell, causing light to scatter and fluorescent dyes to emit 
light at various frequencies. Photomultiplier tubes (PMT) receive the scattered light 
signals and convert them to electrical signals. As a result o f this, cell data are 
collected (Parks et al. 1998).
Generally, there are three types o f data; they are data o f forward scatter, side scatter 
and fluorescence. The forward scatter data estimate the approximate cellular size 
while the side scatter data identify cell complexity and granularity. With these data, 
the dead cells and debris are excluded ( Parks et al. 1998).
The data from fluorescent labeling allows investigation o f cell structure and function.
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Fluorescent dyes are used to label cell structure to generate cell autofluorescence. 
FACS machine collects fluorescent signals from one to several channels 
corresponding to different laser excitation and fluorescent emission wavelength 
(Parks et al. 1998).
In this study, Propidium iodide (PI) was used as a dye for cell cycle analysis. PI dye 
works by binding to DNA in living cells so as to emit fluorescent signals. Following 
this, the relative DNA content of the cells was recorded. As cells in different phase 
have different DNA content, the data shows the proportion o f cells in G l, G2 and S 
phases (Parks et al. 1998).
2.3.2 PI staining if the cells
The cells were scraped off from the plates and were transferred to a 15ml 
centrifugation tubes and were pelleted at 1000 r.p.m. at 4°C for 5 minutes. The cells 
were washed with cold phosphate buffer saline (PBS) (see appendix 4 for the 
preparation) and were pelleted again at 1000 r.p.m. at 4°C for 5 minutes. Afterwards, 
the pellets were resuspended in 300pl of cold PBS. 1ml o f ice-cold 100% ethanol 
were added dropwise to the cells whist vortexing so as to prevent an osmotic shock
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which can damage or even cause unwanted cell death. The cells were stored in -20 °C 
until the day of analysis.
2.3.3 FACS analysis
On the day o f analysis, the cells were pelleted at 1000 r.p.m. at 4°C for 5 minutes. The 
pellets were resuspensed in 300pl of PI buffer (see appendix 5 for the preparation) 
containing 100pg/ml o f PI and 100pg/ml of ribonuclease A. The cells were then 
transferred to FACS tubes and were then incubated in the darkness at 37 °C for 30 
minutes. Afterward, the cells were analyzed by Epics XL flow cytometer (Beckman 
Coulter). Fluorescence was excited by laser beam at 488nm and the signals generated 
were collected at 575nm by a band pass filter. Around 30000 cells were collected for 
analysis. Double discrimination was used to exclude cell clumps. Cell cycle 
distribution was estimated by generating a mathematical model using software 
Multicycle (Phoenix Flow Systems, San Diego, USA).
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2.4 Methods related to qRT-PCR
Materials and Methods
2.4.1 TRIZOL method of RNA isolation
TRIZOL method is a convenient method for the isolation o f total RNA from cells and 
tissues. It is improved from the classical method developed by Chomczynski and 
Sacchi using a mono-phasic solution of phenol and guanidine isothiocyanate. 
TRIZOL Reagent can maintain the integrity of the total RNA while disrupting cells 
and dissolving cell components during sample homogenization or lysis.
The medium in a plate was removed and the cells were washed twice with 5 ml of 
HBBS. 1 ml o f TRIzol solution (invitrogen) was added to the cells after the HBBS 
was removed. The cells were scraped off and were transferred to an autoclaved 
eppendorf. The homogenate was incubated for 5 minutes at room temperature. 
Afterward, 200pl o f chloroform was added and the eppendorf was inverted several 
times to mix. Vortexing in this step is not recommended as this may shear genomic 
DNA which can cause excessive DNA contamination o f the RNA preparation 
(Dieffenbach & Dveksler 2003). The mixture was pelleted at 13000 r.p.m and 4°C for 
15 minutes. The upper aqueous phase, in which RNA remains exclusively, was
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transferred to an autoclaved eppendoff to hich 500pl of isopropanol was added. The 
eppendorf was vortexed to ensure thorough mixing. The mixture was then incubated 
at room temperature for 10 minutes to allow the RNA to precipitate. The mixture was 
pelleted again at 13000 r.p.m and 4°C for 30 minutes. The supernatant was carefully 
removed and the pellet was washed with 1ml of 75% ethanol. The mixture was 
pelleted at 13000 r.p.m and 4°C for 15 minutes. The supernatant was removed and the 
pellet was allowed to air dry for 10 minutes at room temperature. The pellet was then 
resuspended in 30pl DEPC water (see appendix 6 for the preparation). 2pi of the 
sample was taken for estimation o f RNA concentration by spectrometry (see section 
2.4.2.1) and 2pl o f the RNA was run on a 2% agarose gel to check the quality of the 
RNA (see section 2.4.2).
2.4.2 RNA yield and quality determination
The main goal o f RNA isolation is to obtain good yield and quality RNA for 
successful downstream experiments. Generally, there are two ways o f doing this; one 
way is by spectrometry and the other way is by agarose gel electrophoresis. Both the 
methods were used in the study and are described in this section.
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2.4.2.1 Spectrometry
Materials and Methods
Spectrometer is a powerful tool to detect the concentration and the relative quality o f 
RNA and DNA. Generally, it works by recording the absorbance o f 260nm (A260) and 
280nm (A280) to determine the concentration of the nucleic acid and the protein 
content respectively. The RNA content can be calculated by the following formula:
RNA concentration (pg/pl) = A260 X 0.04pg/pl X dilution factor
The RNA quality can be estimated by the A260/A280 ratio. Good quality RNA should 
give the ratio between 1.5 and 2 (Dieffenbach & Dveksler 2003).
The program o f the muti-wavelength was chosen in the spectrometer. 600pl of the 
MilliQ water was added to a cuvette and put into the spectrometer as a blank. The 
calibration button on the screen was selected so that the machine was calibrated in 
accordance with the blank. The water from the cuvette was removed. 2pl of RNA 
solution was mixed with 598pl o f the same MilliQ water which used as a blank. The 
mixture was added to the cuvette. The cuvette was put into spectrometer again. The 
button o f sample running was selected and reading was recorded. The mixture was
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removed and the cuvette was cleaned by the same MilliQ water. If more than one 
sample was used, the procedures were repeated starting from setting up a blank to 
clean the cuvette.
2.4.2.2 Agarose gel electrophoresis
Gel analysis is a good method to estimate the yield and quality o f  RNA. It can be used 
to estimate the average size distribution of RNA and the RNA degradation in a sample.
It resolves RNA by the rate o f migration which depends on the size o f RNA. Ethidium 
bromide can be used to detect RNA in a gel. A RNA ladder (invitrogen) was run in gel 
so that the yield o f the RNA can be compared during visualization. The yield and 
quality can be visualized by using a computer imaging software or directly under UV 
light. Generally, good quality o f the RNA should be resolved in two sharp bands 
which correspond to the 18S and 28S of ribosomal RNA (Dieffenbach & Dveksler 
2003).
Generally, the percentage o f the agarose gel was determined by the kilo base (kb) of 
the nucleic acid to be resolved. 1 % agarose gel can resolve fragment greater than lkb 
while 2.5% can resolve fragment shorter than 1 kb (Dieffenbach & Dveksler 2003). In
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this study, 2.5% agarose gel was used to resolve the nucleic acid sample. To start with, 
agarose power (invitrogen) was dissolved in IX TAE buffer. 2.5% agarose gel means 
2.5g o f the power should be dissolved in every 100ml o f the IX  TAE. The solution 
was then heated in a microwave oven for 3 minutes to facilitate the power to dissolve 
and remove any dissolved gas. The solution was cooled down for 5 minutes and 2pl 
of ethidium bromide was added to every 100ml of the solution. The solution was 
poured into a gel casting apparatus. Gel combs were inserted to the gel casting 
apparatus. The solution was then left at room temperature for 40 minutes to allow the 
gel to solidify.
Once the gel had formed, it was put into a gel tank. IX TAE buffer was poured into 
the gel tank so that the gel was covered by the buffer. The combs were removed. 1 pg 
RNA marker was added to one well of the gel. RNA sample, which mixed with IX 
loading dye (invitrogen) by 1 to 1 ratio, were added to other wells. The gel tank was 
connected to a power supply and the gel was run under 100V. The gel should be 
placed in a right orientation so that the negative RNA could run to the positive pole 
through the gel. The gel was checked periodically by looking at the “solvent font” to 
prevent the RNA from running off the bottom of the gel. Generally, it takes around 90 
minutes to run the RNA. The gel was taken to a computer imaging system (Syngene,
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Synoptics) for image capture. After putting the gel in the system, the Syngene 
program in the computer was selected. The button o f the auto-freeze was selected and 
the image o f the gel was displayed on the screen. The exposure time could be varied 
so as to change to intensity of the signal detected. Once when the signal detected was 
optimized, the button o f the manual freeze was selected and the image could be 
printed out.
2.4.3 DNase 1 treatment of RNA
Isolation of total RNA invariably contain trace amount o f genomic DNA which may 
affect downstream application such as real time PCR. Therefore, it is important to 
remove the genomic DNA. This can be achieved by treating the total isolated RNA 
with RNase-free DNase 1 so as to remove any genomic DNA contamination. The 
procedures are decribed in this section.
Firstly, 20pg of total RNA, 1 OjlxI of the DNase buffer and 1.5pl of the RNase-free 
DNase 1 (Amersham) were added to an autoclaved eppendorf. DEPC-treated water 
was added to make the final volume to lOOpl. The mixture was incubated at 37°C for 
30 minutes, then at 70 °C for 10 minutes to stop the reaction. DEPC-treated water was
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added to the mixture increase the final volume to 200pl. 1 OOjlxI of phenol and lOOpl of 
chloroform were added to the mixture. The mixture was mixed and pelleted at 
13000r.p.m for 15 minutes. The aqueous upper phase was transferred to an autoclaved 
eppendorf and 200pl chloroform was added. The mixture was mixed and pelleted 
again at 13000r.p.m for 15 minutes. The aqueous upper phase was transferred to an 
autoclaved eppendorf. RNA was precipitated with 0.1 volume o f 5M NaCl (20pl) and 
2.5 volumes o f 100% ethanol (500pl) for at least 2.5 hours at -20°C. The sample was 
pelleted at 13000 r.p.m and 4°C for 30 minutes. The supernatant was removed and the 
pellet was washed with 180pl o f 100% ethanol to remove extra salts. The sample was 
pelted again at 13000 r.p.m and 4°C for 10 minutes. The supernatant was removed and 
the pellet was allowed to air dry for 10 minutes. 20pl o f DEPC-treated water was 
added to resuspend the pellet. 2pi o f the sample was taken out for the spectrometer 
described in section 2.4.2.1 and 0.5pg of RNA was run on a 2% agarose gel to check 
for the quality (see section 2.4.2.2).
2.4.4 cDNA synthesis
cDNA was prepared from RNA for subsequent PCR reactions. To do this, lpg of 
RNA was transferred to an autoclaved eppendorf for cDNA synthesis. 2.5pi of
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random hexamer primers (lOOpg/ml) was added. DEPC-treated water was added to 
bring the final volume to 11 pi. The sample was heated at 70°C for 10 minutes and 
then cooled on ice immediately. After brief spinning, 8pl o f master mix (Table 2.4) 
was added. The mixture was then mixed and briefly spun. The mixture was then 
incubated at room temperature for 2 minutes, lpl of superscript 2 (invitrogen) was 
added to the mixture. The mixture was mixed by pipetting up and down several times 
and was incubated at room temperature for another 10 minutes. Afterwards, the 
mixture was incubated at 42°C for 1 hour. Finally, the mixture was incubated at 70 °C 
to stop the enzyme reaction. The mixture was then stored at -20 °C.
Reagents: Volume for one reaction
5 X first strand buffer 4pl
0.1 DDT 2 pi
lOmM dNTP lpl
RNasin lpl
Table 2.4 The volume o f  the reagents used to formulate a master mix for a 20gl reaction o f  the cDNA  
synthesis.
It is important to set up a negative control for each sample to see whether there is still 
some genomic contamination. A negative control can be set up by following the whole 
processes o f cDNA synthesis except lpl DECP water is added rather lp l of
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superscript 2. If  DNA amplification is recorded in the negative control in the 
subsequent quantitative PCR experiment, this means genomic DNA is present and the 
sample should be reprocessed from the DNA digestion.
2.4.5 Quantitative RT-PCR
Quantitative RT-PCR (qRT-PCR) was carried out to quantify the amount o f cDNA 
synthezed form the mRNA of Bm-3b, cyclin D l, cyclin E and GAPDH in ND7 and 
MCF7 from various sets o f experiments. Generally, the qRT-PCR technology allows 
the absolute quantity o f mRNA found in a sample to be ascertained by the 
incorporation of light emitting dyes into the PCR product.
2.4.5.1 Sequence-specific Taqman probes
In the experiment, Taqman probe assay system (quantiTect assay system-Qiagen) was 
used. This assay system utilizes a sequence specific dual labeled probe, which has a 
fluorophore dye incorporated to the 5’ end of the sequence and a quencher dye at the 
3’ end. During the extension phase if  the PCR the probe is cleaved and the fluorescent 
and quenching dyes are separated. This results in the emission of a detectable
57
Chapter 2 Materials and Methods
fluorescent signal that is produced in a proportional manner to the accumulating PCR 
product.
As the probe system cannot distinguish the product resulting from a cDNA template 
or a genomic DNA template, it was necessary to ensure that the PCR products were 
not a result o f contamination. Therefore as with all the RT-PCR reactions carried out, 
cDNA samples prepared without inclusion of the reverse transcriptase were included 
in each run to determine if there was any genomic DNA contamination present.
2.4.5.2 Standard curve
Standard curve was generated as a reference to estimate the amount o f the cDNA 
present in each sample. Four different standard curves were generated for the four 
different gene o f interest in the study—Bm-3b, cyclin D l, cyclin E and GAPDH. 
DNA of the genes o f interest was collected and amplified by PCR as described in 
section 2.4.5.4. The products for the standard curve were resolved by a 2.5% agarose 
gel (please see section 2.4.2.2). The products were directly visualized under UV light 
and were cut out from the gel to recover the DNA for generation of standard curve 
(please see section 2.4.5.3).
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2.4.5.3 Gel extraction
Materials and Methods
The gel slice was put in an autoclaved eppendorf and the weight of the gel was 
estimated by using an electronic balance. 3 volumes o f buffer QG was added to 1 
volume of gel. For example, 300pl o f buffer QG should be added to lOOmg. The 
mixture was incubated at 50°C for 10 minutes. In order to help dissolve the gel, the 
mixture was vortexed every 2 minute during the incubation. 1 gel volume of 
isopropanol was added and mixed after the gel was dissolved. This means lOOpl was 
added to lOOmg of gel. The mixture was transferred to a QIAquick spin column 
which was placed in a 2ml collection tube. The mixture was then centrifuged for 1 
minute at 13 r.p.m. The flow-through was discarded and 0.5ml o f buffer QG was 
added to the column to remove all traces of agarose. The column was centrifuged for 
1 minute at 13 r.p.m. again. The flow-through was discarded and 0.75 ml o f buffer PE 
was added to the column. The column was centrifuged for 1 minute at 13 r.p.m. again 
and the flow-through was discarded. The column was centrifuged for 1 minute at 13 
r.p.m again to remove residual ethanol from buffer PE. The column was placed into an 
autoclaved eppendorf. 50 pi DEPC water was added to the center o f the member in the 
column and was centrifuged for 1 minute at 13 r.p.m. This step is to elute DNA into 
the eppendorf. The DNA was stored in -20°C.
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The concentration o f the DNA isolated was quantified by spectrometry (please see 
section 2.4.2.1) and gel eletrophoresis (please see section 2.4.2.2). Serial dilution was 
performed subsequently to prepare DNA with different concentrations. Four types o f 
standard curve samples were prepared; they are cyclin D l, cyclin E, GAPDH and 
Bm-3b(total). The range of concentration prepared for the standard curve samples was 
based on the level o f the gene expression in cells (Table 2.4). These standard samples 
were used in every experiment so that variations between experiments would be 
minimized.
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50000fg Cyclin D l; Cyclin E; GAPDH
lOOOOfg Cyclin D l; Cyclin E; GAPDH
lOOOfg Cyclin D l; Cyclin E; GAPDH; 
Bm-3b(total)
500fg Cyclin D l; Cyclin E; GAPDH; 
Bm-3b(total)
lOOfg Cyclin D l; Cyclin E; GAPDH; 
Bm-3b(total)
Ifg Cyclin D l; Cyclin E; GAPDH; 
Bm-3b(total)
O.lfg Cyclin D l; Cyclin E; GAPDH; 
Bm-3b(total)
O.OOlfg Cyclin D l; Cyclin E; GAPDH; 
Bm-3b(total)
O.OOOOlfg Cyclin D l; Cyclin E; GAPDH; 
Bm-3b(total)
Table 2.4 The concentrations o f  D NA prepared for standard curve for real time PCR experiment. Four 
types o f  standard curve samples were generated; they were cyclin D l,  cyclin E, GAPDH and 
Bm-3b(total).
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2.4.5.4 qRT-PCR reaction
Materials and Methods
The reactions were performed in a final volume of 20pl in thin walled microcentrifuge 
tubes. lOpl master mix (Qiagen) was added to a well o f the tubes. Following lp l of 
the Taqman probe was added to the well, 8pl of DEPC water and 1 pi of cDNA were 
added.
The tubes were then placed in a controlled heat block in the qRT-PCR machine (MJ 
research) and subjected to a thermal cycle as shown in Table 2.5. The results obtained 
from the reactions were analyzed using Opticon (MJ research).
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Step Temperature Duration Process
1 95°C 15 min Activate of 
enzyme
2 95°C 30 sec Denature o f cDNA
3 60°C 30 sec Annealing of 
cDNA
4 72°C 30 sec Extension of cDNA
5 Plate read
Table 2.5 The thermal cycling profile required for the Taqman probe assay system .
In order to compare the mRNA levels of Bm-3b, cyclin D l and cyclin E measured, 
the mRNA levels o f GAPDH from each samples were quantified and the values were 
used to normalize the values obtained from mRNA levels o f Bm-3b, cyclin Dl and 
cyclin E measured from each sample. GAPDH is used as a reference for comparison 
because it is a house-keeping gene and is assumed that the mRNA level of GAPDH in 
the same type of cells is more or less the same.
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2.5 Methods related Western Blotting
Materials and Methods
2.5.1 Preparation of samples for protein assay
Cells seeded on the Petri dish was washed twice with 5ml o f HBBS. 150pl of 2X 
sample buffer (see 7 appendix for the preparation) was added to the dish and then the 
cells were scraped off into the buffer by using a scraper. The mixture was transferred 
to an autoclaved eppendorf and 16pl o f (3-mercaptoethanol was added before being 
boiled at 100°C for 5 minutes. lOpl was taken for protein assay.
2.5.2 Protein assay
Protein concentration in the suspension was determined by Bradford method. 40pi of 
Bradford Reagent were added into the wells containing standard or samples. Samples 
were subjected to absorbance measurement by spectrophotometer at 595nm.
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2.5.3 SDS-PAGE
Materials and Methods
The percentage o f acrylamide used depends on the size o f the protein to be separate. 
Lower percentage of gel was used to resolve larger size of protein.
12.5% SDS resolving gel solution was prepared by mixing 15 ml of 30% 
acrylamide stock solution, 9 ml o f gel running buffer (see appendix 8 for preparation) 
and 12 ml o f MilliQ water. 147 pi o f 10 % fleshly prepared ammonium persulphate 
(APS) (see appendix 9 for preparation) and 15pi TEMED were then added to the 
mixture. A gel casting apparatus was set up according to manufacturer’s instructions, 
and the mixture was then loaded into the gel casting apparatus. Water-saturated 
n-butanol was added on the top o f the gel to eliminate formation o f meniscus gel and 
to exclude oxygen, which would otherwise inhibit polymerization on the gel surface. 
The gel was allowed to stay at room temperature for 1 hour for polymerization. 
Stacking gel solution was prepared by mixing 2ml of 30% acrylamide stock solution, 
3ml of gel stacking buffer (see appendix 10 for preparation) and 7ml o f MilliQ water. 
100 pi of 10 % fleshly prepared APS and lOpl TEMED were then added to the 
mixture.
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The water-saturated n-butanol on the resolving gel was removed and a comb was 
inserted between the glasses. Stacking gel mixture was loaded on the top of the 
resolving gel. The gel was incubated at room temperature for 1 hour for 
polymerization o f the stacking gel. Afterwards, the comb was removed from the gel 
and wells were rinsed with tank buffer. 60 pg of protein extract (10 pi o f extract and 
sample buffer mixture) and protein marker (lOpl) (invitrogen) were loaded into the 
wells and the gel eletrophoresis chamber was filled with running buffer (see appendix 
11 for preparation). Proteins with different size were resolved at a constant current 
(40-50mA/gel) at room temperature for 2-3 hours.
2.5.4 Western Blotting
After the gel running process had completed, the gel was removed from the gel 
apparatus and the stacking gel was removed. The separating gel, which resolved the 
proteins, was used for western blotting.
Proteins resolved by the gel were transferred to Hybond-C membranes using a 
wet-transfer method. Generally, the membrane and two pieces o f 3mm Whatman 
paper were cut to the size o f the gel. The membrane, the 3mm paper, two sponges
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were soaked in IX transfer buffer (see appendix 12 for preparation), and were placed 
into the transfer gel in the following sequence:
Sponge —» 3mm paper -> gel —> membrane -> 3mm paper —» Sponge
Special care was taken to ensure that all air bubbles were removed so that the transfer 
process was not affected. The transfer apparatus was assembled and was putted in a 
transfer chamber filled up with transfer buffer. The transfer apparatus must be placed 
in an orientation that the gel was faced to the negative pole while the membrane was 
faced to the positive pole so that the proteins were able to migrate to the membrane 
through the electric field. The transfer process was carried out overnight under 30mA 
at 4°C.
2.5.5 Probing with antibodies
After the transfer process, the membrane was taken out from the apparatus and was 
blocked by incubation with 1% non-fat milk in PBS and 0.1% o f tween 20 (MPT) (see 
appendix 13 for preparation) for 1 hour at room temperature. The blot was 
subsequently incubated with primary antibody (see appendix 14 for preparation) for 1
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hour at room temperature. The choice of primary antibody depends on the protein o f 
interest. The blots were then washed five times with MPT in order to remove 
unbounded antibody. Each wash was for 5 minutes. The blot was then incubated with 
a Horseradish peroxide (HRP) conjugated secondary antibody (see appendix 15 for 
preparation) for 1 hour at room temperature. Afterwards, the blot was washed four 
times with MPT to remove the unbounded secondary antibody and was washed one 
time with 0.1% tween 20 in PBS to remove the non fat milk. Again, each wash was 
for 5 minutes.
2.5.6 Visualization of proteins
The membrane was placed on a sheet of cling film with protein side up, after the 
excess washed buffer was drained. Two reagents of the enhanced chemiluminescence 
system (ECL) were mixed in a ratio of 1:1 and were added to the membrane. Usually,
3 ml of the ECL mixture was added to a membrane, but the actual volume was 
dependent on the size o f the membrane. After 1 minute incubation with the solution at 
room temperature, the excess reagent was drained off and the blot was wrapped and 
placed protein side up in an X-ray film cassette (Hypercasstte). The cassette was then 
taken over to a dark room for autoradiography film development.
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In a dark room, a sheet of autoradiography film was placed on top o f the membrane 
for detection of the resulting light emission. The exposure times were dependent on 
the signal strength and therefore were highly variable. It could vary from 30 seconds 
to 1 hour. Afterwards, the film was put in a developer and protein bands were 
visualized.
2.5.7 Striping the antibody
Stripping o f the membrane allows the membrane to be re-probed with another 
antibody. It was simply done by washing the membrane in 0.2M sodium hydroxide 3 
times. The wash was 5 minutes for each time. Afterwards, the membrane was washed 
with PBS for 3 times. Again, the wash was 5 minutes for each time. The membrane 
was blocked and reprobed as described (please refer to section 2.5.6).
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Chapter Three 
Results
Previous studies have showed that high level of Bm-3b promotes cell proliferation in 
cancer cells (Irshad et al. 2004;Sonia et al. 2005). Moreover, Bm-3b has been found 
to upregulate the expression o f CDK4 and cyclin D1 (Samady et al. 2004). Therefore, 
Bm-3b may enhance cell proliferation by regulating the expression o f various cell 
cycle regulators. However, the expression pattern of Bm-3b during the cell cycle and 
when it activates its target genes such as cyclin D1 are not known. Therefore, in this 
study, the expression pattern o f Bm-3b and the relationship between Bm-3b and 
cyclin D1 in ND7 and MCF7 cells were studied. The relationship between Bm-3b and 
cyclin E was also investigated.
A high level of Bm-3b expression has been observed in various cancer cells (Irshad et 
al. 2004;Sonia et al. 2005). However, the cause of the increase expression of Bm-3b 
in the cancer cells it is still to be elucidated. In this study, a carcinogen 
benzo(a)pyrene was used to treat the cells to investigate whether this carcinogen could 
increase the level of Bm-3b in the cells or not.
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Thus, in this study, three different sets of experiments were carried out on ND7 cells; 
they were the cell cycle arrest o f the cells following various treatments (refer to 
section 3.1), the addition o f full serum medium after cell growth in serum free 
medium (refer to section 3.2) and cell exposure to a carcinogen benzo(a)pyrene (refer 
to section 3.3). FACS analysis, quantitative RT-PCR and western blotting were 
conducted in parallel for each experiment.
The same sets o f experiments were to be carried out in parallel on MCF7 cells. 
However, due to the limitation o f time, only the experiment regarding to the cell cycle 
arrest o f the cells under various treatments was performed (refer to section 3.4).
3.1 The experiment on cell cycle arrest of ND7 cells following various treatments
In this study, the relationship o f Bm-3b, cyclin D1 and cyclin E in a specific phase of 
the cell cycle were studied. To do this, 1X106 ND7 cells were seeded on Petri dishes 
and were subjected to various treatments including 5-fluorouracil, hydroxyurea, 
colchicines, doxorubicin and etoposide. The concentrations o f the various drugs were 
chosen based on experiment currently undertaken in our laboratory that were shown 
to effectively arrest cells in a specific phase without causing massive cell death. The
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cells were harvested after 12 hours o f treatments and were processed for FACS 
analysis, quantitative RT-PCR and western blotting (please refer to chapter 2 for 
details).
3.1.1 The changes in percentage of ND7 cells in different stages of the cell cycle 
following various treatments
To confirm the ND7 cells were arrested in a particular phase in the cell cycle 
following specified treatments, FACS analysis was carried out. In addition, cells 
growing in DMSO were also used as a control for cells treated with colchicine, 
doxorubicin and etoposide. The reason for this was because DMSO was the solvent of 
those drugs. Thus, this control was used to ensure that the effects observed in cells 
treated with colchicine, doxorubicin and etoposide were not caused by the solvent.
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The percentage of ND7 cells in different phases of the cell cycle
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Figure 3.1 The percentage o f  N D 7 cells in different phases o f  the cell cycle following various 
treatments. IX106 o f  cells were plated out in full serum medium and were left on for 12 hours. 
Treatments including 5-fluorouracil (5-FU), hydroxyurea (HU), colchicine (COL), doxorubicin (DOX) 
and etoposide (ETOP) were added for 12 hours. DMSO, which was used as a control, was added to the 
cells for 12 hours. All the cells were harvested at the same time for FACS analysis.
As shown in Figure 3.1, ND7 cells treated with 5-fluorouracil and hydroxyurea were 
arrested in the G1 phase when compared with the untreated control, where 58.7% and 
58.4% of cells were arrested in G1 phase respectively. These drugs were the most 
effective at arresting cells in the G1 phase of the cell cycle.
From the results of the FACS analysis (Figure 3.1), cells treated with colchicine, 
doxorubicin and etoposide were arrested in G2/M phase when compared with the 
untreated and DMSO controls. Colchicine, doxorubicin and etoposide were able to
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arrest 88.5%, 86.5% and 70% o f cells respectively in the G2/M phase.
3.1.1.1 Optimization of the concentrations of 5-fluorouracil and hydroxyurea to 
arrest more ND7 cells in G1 phase of the cell cycle
From the results of FACS analysis, 60% of cells were arrested in G1 phase following 
the treatments with 5-fluorouracil and hydroxyurea. As we wished to arrest up to 80% 
of ND7 cells in the G1 phase o f the cell cycle, further experiments were carried out to 
test whether higher concentrations o f treatments with the 5-fluorouracil and 
hydroxyurea could arrest more cells in G1 phase of the cell cycle. In this experiment, 
the concentration o f 5-fluorouracil used to treat cells was increased from lpg/ml to 
2.5pg/ml whereas the concentration of hydroxyurea used to treat cells was increased 
from ImM  to lOmM.
From the results (Figure 3.2), an increase in the concentrations of 5-fluorouracil and 
hydroxyurea did not induce more cell arrest in G1 phase o f the cell cycle. Different 
concentrations of 5-fluorouracil gave a very similar cell cycle distribution results. 
Interestingly, an increase in the hydroxyurea concentration even reduced the 
percentage o f cells distributed in the G1 and S phase. Therefore, for the subsequent
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study, 1 jig/ml of 5-fluorouracil and ImM of hydroxyurea were used to treat cells.
The percentage of ND7 cells in different phases of the
cell cycle
■  S phase 
□  G2/M phase
G1 phase
o>
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Figure 3.2 The percentage o f  N D 7 cells in different phases o f  the cell cycle follow ing treatments with 
5-fluorouracil and hydroxyurea at different concentrations. IX106 o f  cells were plated out in full serum 
medium and were left for 12 hours. Treatments including lmg/ml o f  5-fluorouracil, 2.5mg/ml o f  5-FU, 
ImM o f  hydroxyurea (HU), and lOmM o f HU, were added for 12 hours. All the cells were harvested at 
the same time for the FACS analysis.
In summary (refer to Table 3.1), a higher percentage o f ND7 cells treated with 
5-fluorouracil and hydroxyurea were arrested in G1 phase whereas a higher 
percentage of ND7 cells treated with colchicine, doxorubicin and etoposide resulted in 
cell arrest in the G2/M phase. These results confirmed that the drugs were able to 
arrest cells in a specific phase o f the cell cycle, providing a model for further study of 
the mRNA levels of Bm-3b, cyclin D1 and cyclin E in cells arrested at different stages 
o f the cell cycle.
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Cell cycle arrest (%)
G1 S G2/M
Full growth 
medium for 24 
hours
34 52.3 13.7
5-fluorouracil
(lUg/ml)
58.7 41.3 0
Hydroxyurea
(ImM)
58.4 41.6 0
Colchicine (lpM ) 6.1 5.4 88.5
Doxorubicin
(lpM )
2.5 11 86.5
Etoposide (lOpM) 2 28 70
DMSO (0.1%) 40.7 45.3 14
Table 3.1 The summary o f  the cell arrest o fN D 7  cells following various treatments.
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3.1.2 Changes in the mRNA levels of Brn-3b, cyclin D1 and cyclin E in ND7 cells 
following various treatments
In parallel with the FACS analysis, mRNA levels of Bm-3b, cyclin D1 and cyclin E in 
ND7 cells following various treatments were investigated by quantitative RT-PCR. 
The cells were seeded and treated in the same conditions as that for FACS analysis. 
RNA were extracted from the cells and were used for cDNA synthesis. By 
quantitative RT-PCR, the mRNA levels of Bm-3b, cyclin D1 and cyclin E were 
normalized against the GAPDH control.
As shown in Figure 3.3, the mRNA levels of Bm-3b in ND7 cells following 
treatments with 5-fluorouracil and hydroxyurea increased when compared to the 
untreated control. In particular, the cells treated with 5-fluorouracil showed a higher 
level of Bm-3b level than the cells treated with hydroxyurea. However, upon 
treatment with colchicine, doxorubicin and etoposide, the mRNA levels o f Bm-3b 
were low compared with the untreated and DMSO control.
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The mRNA level of Brn-3b normalized to GAFDH
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Figure 3.3 The mRNA level o f  Bm -3b in the ND 7 cells following various treatments. The mRNA level 
o f  the Bm -3b was normalized to the mRNA level o f  GAPDH in the same sample used. The experiment 
was carried out in the same conditions as the FACS analysis as stated in Figure 3.1. The mRNA levels 
o f Bm-3b and GAPDH in the ND7 cells were tested by quantitative RT-PCR.
The mRNA levels o f cyclin D1 in these treated cells are shown in Figure 3.4. 
Following the treatment with 5-fluorouracil and hydroxyurea, the mRNA levels of 
cyclin D1 in the ND7 cells increased when compared to the untreated control. 
Interestingly, the increase in cyclin D1 mRNA level with these treatments was similar 
to the increase o f Bm-3b in these cells. The mRNA level o f cyclin D1 in the ND7 
cells treated with colchicine, doxorubicin and etoposide was low when compared with 
the untreated and DMSO controls.
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The mRNA level of cydin D1 normalized to GAPDH
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Figure 3.4 The mRNA level o f  cyclin D1 in the ND7 cells following various treatments. The mRNA 
level o f the cyclin D1 was normalized to the mRNA level o f  GAPDH in the same sample used. The 
experiment was carried out in the same conditions as the FACS analysis as stated in Figure 3.1. The 
mRNA levels o f  cyclin D1 and GAPDH in the ND7 cells were tested by quantitative RT-PCR.
The mRNA levels of cyclin E in the ND7 cells were also measured. From Figure 3.5, 
it shows that the mRNA level of cyclin E were higher in the cells treated with 
5-fluorouracil and hydroxyurea when compared to the untreated control. Treatment 
with hydroxyurea induced a higher increase in cyclin E mRNA level in the ND7 cells 
than that of the treatment with 5-fluorouracil. Again, the mRNA levels of the cyclin E 
in the cells treated with colchicine, doxorubicin and etoposide was low when 
compared with the untreated and DMSO controls.
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The mRNA level of cyclin E normalized to GAPDH
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Figure 3.5 The mRNA level o f  cyclin E in the ND7 cells following various treatments. The mRNA 
level o f  the cyclin E was normalized to the mRNA level o f  GAPDH in the same sample used. The 
experiment was carried out in the same conditions as the FACS analysis as stated in Figure 3.1. The 
mRNA levels o f  cyclin E and GAPDH in the ND 7 cells were tested by quantitative RT-PCR.
Taken together, high mRNA level of Bm-3b was observed when a high percentage of
cells were arrested in the G1 phase of the cell cycle whereas the mRNA level of
Bm-3b was low in the G2/M phase. This result suggests that Bm-3b levels changes as
the cells progress in the cell cycle. Importantly, from the results o f the quantitative
RT-PCR, it was observed that the changes in the mRNA levels o f cyclin D1 and cyclin
E also correlated with the mRNA level of Brn-3b. When Brn-3b mRNA level
increased, the cyclin D1 and cyclin E mRNA levels also increased whereas when the
Bm-3b mRNA level decreased, the cyclin D1 and cyclin E mRNA levels decreased.
The similarity in pattern of the mRNA levels o f Bm-3b, cyclin D1 and cyclin E at
different stages of the cell cycle suggests that Bm-3b may play a role in regulating the
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expression of cyclin D1 and cyclin E.
3.1.3 The expression of Brn-3b in ND7 cells following various treatments
Western blotting was carried out to investigate the protein levels o f Bm-3b in the ND7 
cells following the specified treatments. As before the cells were seeded and treated 
under the same conditions as that for FACS analysis and quantitative RT-PCR. 
Proteins were extracted from the cells as described in section 2.3. Bm-3b was probed 
for and visualized using ECL. p-Actin was also probed to show that same amount of 
proteins were loaded.
From the results, no clear signals were observed (data not shown). The reason for this 
might be due to the fact that not enough proteins were loaded. However, due to the 
limitation o f time, the western blotting analysis was not repeated.
3.2 Synchronization of cells to analyze for Brn-3b levels
The previous experiment to analyze changes in the mRNA levels o f Bm-3b, cyclin D1 
and cyclin E at different phases of the cell cycle following specified treatments
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showed that the mRNA level of Bm-3b correlated to that o f cyclin D1 and cyclin E. 
To further investigate whether the mRNA levels of Bm-3b and cyclin D1 change in 
synchronized cells to allow cells to progress in a uniform manner through the cell 
cycle, this study was untaken. Cells were synchronized at G1 phase by transferring 
serum free medium for an optimum time period to induce cell cycle arrest (refer to 
section 3.3.1), and then transferred back to full serum medium afterwards so that the 
cells resumed their cell cycle progression in a synchronized manner. Serum free 
medium was used to synchronize the cells because previous studies demonstrated that 
after transferred of ND7 cells into serum free medium, they are able to undergo cell 
cycle arrest at G1 phase o f the cell cycle. The cells are then able to resume cycling in 
the cell cycle once full growth medium was added (Budhram-Mahadeo et al. 1994; 
Budhram-Mahadeo et al. 1995). In this experiment, the cells were harvested at 3, 6, 
12, 24, 36 and 48 hours after being transferred back to full serum medium for FACS 
analysis, quantitative RT-PCR and western blotting.
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3.3.1 Optimization of the time period for cell growth in serum free medium in 
order to induce cell cycle arrest without excessive cell death
The period of growth of ND7 cells in serum free medium is critical as not all the cells 
will undergo cell cycle arrest if  the exposure time in serum free medium is too short 
whereas if the exposure time of cells in serum free medium is too long, increased cell 
death will occur so that fewer cells will be available for analysis. The optimum 
exposure time of cells in serum free medium depends on two factors— the percentage 
o f cells that survive but arrest in the cell cycle and the percentage o f cell death. To 
address this, an initial experiment was conducted to find out the optimum exposure 
time of cells in serum free medium.
3.3.1.1 The percentage of ND7 cells arrested in G1 phase and the percentage of 
cell death after transferring to serum free medium for 24, 48 and 72 hours
In this experiment, ND7 cells were cultured in full growth medium and serum free 
medium for 24, 48 and 72 hours respectively. The cells grown in full growth medium 
were used as controls to compare changes seen in the cells grown in the serum free 
medium at the three time points. Cells were harvested at appropriate time points for
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FACS analysis and quantitative RT-PCR for testing the Bm-3b mRNA level.
As shown in Figure 3.6, the cells cultured in serum free medium for 48 hours showed 
the highest percentage o f cells arrested in G1 phase whereas cells cultured in serum 
free medium for 72 hours showed the lowest percentage o f cells arrested in G1 phase 
but the highest percentage of cells arrested in the S phase. For the ND7 cells cultured 
in the full growth medium for 24, 48 and 72 hours, they showed a similar cell cycle 
distribution pattern with more cells distributed in the S phase.
The percentage of cell death o f ND7 cells cultured in full growth medium and serum 
free medium for 24, 48 and 72 hours were also determined by FACS analysis. As 
shown in Table 3.2, the highest cell death was recorded in cells cultured in serum free 
medium for 72 hours, and the lowest cell death was recorded in cells cultured in 
serum free medium for 24 hours. The percentage of cell death o f ND7 cells cultured 
in full growth medium for 24, 48 and 72 hours remained low, approximately 2%.
84
Chapter 3 Results
The percentage of ND7 cells in different phases of the
cell cycle
G1 phase 
■ S phase 
□ G2/M phase
Figure 3.6 The percentage o f  N D 7 cells in different phases o f  the cell cycle after culturing for 24, 48 
and 72 hours in full growth medium and serum free medium respectively. 1X106 o f  cells were plated in 
full growth medium for 24 hours and in serum free medium for 24, 48 and 72 hours respectively. 2X 105 
cells were plated in full growth medium for 48 and 72 hours. The cells were harvested at appropriate 
time points for FACS analysis.
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24 hours 48 hours 72 hours
% of cell death in 
FGM
2% 3% 2.5%
% of cell death in 
SFM
2.5% 23% 47%
% o f cells arrested 
in G1 in FGM
36.3 33.9 35.5
% of cells arrested 
in G1 in SFM
45.8 51.35 24.35
Table 3.2 The percentage o f  cell death and the G1 arrest in the cell cycle induced by growing in full 
growth medium (FGM) and serum free medium (SFM) for 24, 48 and 72 hours respectively.
Since the main aim of the experiment was to synchronize cells at a particular phase of 
the cell cycle and then allow the cells to go back into the cell cycle, serum free 
exposure for 48 hours was the optimum time period as it resulted in high percentage 
of cells arrest in G1 phase and the cell death rate was acceptable.
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3.2.1.3 The mRNA levels of Brn-3b and cyclin D1 in ND7 cells cultured in full 
growth and serum free media for 24, 48 and 72 hours
The levels of Bm-3b mRNA and cyclin D1 mRNA in the ND7 cells cultured in both 
full growth medium and serum free medium for 24,48 and 72 hours respectively were 
investigated by quantitative RT-PCR. The levels of Bm-3b mRNA and cyclin D1 
mRNA were normalized to GAPDH.
The results (Figure 3.7) clearly showed that the level of Bm-3b mRNA decreased 
when cells were cultured in serum free medium compared with the level of Bm-3b 
mRNA of cells cultured in full growth medium for the same period o f time. Moreover, 
the level of cyclin D1 mRNA followed the same trend as the level of Bm-3b mRNA 
(Figure 3.8)— the level of cyclin D1 mRNA increased when the level o f Bm-3b 
mRNA increased; the level o f cyclin D1 mRNA decreased when the level o f Bm-3b 
mRNA decreased. This observation was consistent with the observation in the 
previous experiment to analyze changes in the mRNA levels o f Bm-3b, cyclin D1 and 
cyclin E at different phases o f the cell cycle following specified treatments.
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The mRNA level of Brn-3b normalized to GAPDH
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Figure 3.7 The mRNA level o f  Bm -3b in the ND 7 cells after culturing for 24, 48 and 72 hours in full 
growth medium and serum free medium respectively. The mRNA level o f  the Bm -3b was normalized 
to the mRNA level o f  GAPDH in the same sample used. The experiment was carried out in the same 
conditions as the FACS analysis as stated in Figure 3.6. The mRNA levels o f  Bm -3b and GAPDH in 
the ND 7 cells were tested by quantitative RT-PCR.
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Figure 3.8 The mRNA level o f  cyclin D1 in the ND7 cells after culturing for 24, 48 and 72 hours in full 
growth medium and serum free medium respectively. The mRNA level o f  the Bm-3b was normalized 
to the mRNA level o f GAPDH in the same sample used. The experiment was carried out in the same 
conditions as the FACS analysis as stated in Figure 3.6. The mRNA levels o f  cyclin D1 and GAPDH in 
the N D 7 cells were tested by quantitative RT-PCR.
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3.2.2 The percentage of ND7 cells distributed in different phases of the cell cycle 
after being transferred back to full growth medium
Following the optimization for treating cells in serum free medium, the experiment of 
transferring ND7 cells back to full growth medium was performed. After 48 hours of 
growth in serum free medium, the ND7 cells were transferred back to full growth 
medium containing 20% FCS for 3 (+FGM 3h), 6 (+FGM 6h), 12 (+FGM 12h), 24 
(+FGM 24h), 36 (+FGM 36h) and 48 (+FGM 48h)hours respectively. The cells were 
then harvested at appropriate time points for FACS analysis, quantitative RT-PCR and 
western blotting.
The distribution o f the cells at different phases of the cell cycle after they were 
transferred back to full growth medium at different intervals was estimated by FACS 
analysis. As shown in Figure 3.9, after 48 hours in serum free medium (NS 48h), 43% 
of cells were arrested in the G1 phase. After being transferred back to full growth 
medium, the cells started progressing through the cell cycle again. From the results, 
the cells being transferred to full growth medium containing 20% FCS for 3 and 6 
hours showed that the percentage of cells in G1 phase decreased while a similar 
percentage o f cells in G2/M phase increased. This suggested that the cells
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synchronized in the G1 phase o f the cell cycle induced by serum starvation were 
progressing from G1 phase to S phase while similar amount of cells were progressing 
from the S phase to the G2/M phase. For +FGM 12h, as the percentages of cells in G1 
phase of the cell cycle were higher than that of the +FGM 6h while the percentages of 
cells in S phase of the cell cycle were lower than that o f the +FGM 6h, this suggested 
that some cells were progressing from the S phase to the G2/M phase while some of 
the cells were progressing from the G2/M back to the G1 phase o f the cell cycle. 
From the results of +FGM 24h, higher percentages of cells in the S phase and the 
G2/M phase were observed compared with the +FGM 12h, this suggested that the 
some of the cells of +FGM 24h were progressing from the G1 phase to the S phase of 
the cell cycle while some of the cells of +FGM 24h were progressing from the S 
phase to the G2/M phase of the cell cycle. Moreover, as the percentage of cells of 
+FGM 24h distributed in G1 phase was lower than that of +FGM 12h, this suggested 
that most o f the cells were not progressing back to G1 phase o f the cell cycle. The 
cells of +FGM 36h showed a similar cells distribution pattern to the CTR. However, 
as the percentage o f cells o f +FGM 36h in the S phase o f the cell cycle was higher 
than that o f the CTR, this suggested that some of the cells were progressing through 
the S phase o f the cell cycle. For +FGM 24h, it showed a high percentage of cells 
distributed in the S phase, this indicated that most of the cells were progressing
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through the S phase of the cell cycle.
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Figure 3.9 The percentage o f  N D 7 cells in different phases o f  the cell cycle after the cells were cultured 
in full growth medium for 48 hours (CTR), serum free medium for 48 hours (NS 48h) and full growth 
medium containing 20% FCS for 3 (+FGM 3h), 6 (+FGM 6h), 12 (+FGM 12h), 24 (+FGM 24h), 36 
(+FGM 36h) and 48 hours (+FGM 48h) respectively after being transferred back from serum free 
medium. 2X 105 o f  cells were plated out in full growth medium for 48 hours whereas lX 106o f  cells 
were plated out in serum free medium for 48 hours. The cells were transferring back to full growth 
medium containing 20% FCS for 3, 6, 12, 24, 36 and 48 hours respectively after growing in serum free 
medium for 48 hours. The cells were harvested at appropriate time points for FACS analysis.
91
Chapter 3 Results
3.2.3 The changes of mRNA levels of Brn-3b, cyclin D1 and cyclin E in ND7 cells 
transferred back to full growth medium after 48 hours of growth in serum free 
medium
The mRNA levels o f Bm-3b and cyclin D1 in the ND7 cells after being transferred 
back to the full growth medium were estimated by quantitative RT-PCR in parallel to 
the FACS analysis. The cells were seeded and treated in the same conditions as that 
for FACS analysis. RNA were extracted from the cells and were used for cDNA 
synthesis. By quantitative RT-PCR, the mRNA levels of Bm-3b and cyclin D1 were 
analyzed and normalized against GAPDH.
From the results (Figure 3.10), the mRNA level of Bm3b decreased when the cells 
were cultured in serum free medium when compared with the untreated control. The 
mRNA level o f Bm3b increased after 3 and 6 hours of cells being transferred back to 
full growth medium. However, the mRNA levels of Bm3b remained low after 12, 24, 
36 and 48 hours after transferred back to full growth medium.
As shown in Figure 3.11, the mRNA level of cyclin D1 decreased when the cells were 
cultured in serum free medium when compared with the untreated control. After 3 and
92
Chapter 3 Results
6 hours of cells being transferred back to full growth medium, the mRNA level of 
cyclin D1 increased in both cases. However, the mRNA levels of cyclin D1 were low 
after 12, 24, 36 and 48 hours o f cells being transferred back to full growth medium. 
Again, the mRNA level of cyclin D1 followed the trend o f the mRNA level of Bm-3b.
Figure 3.10 The mRNA level o f  Bm-3b in ND7 cells after the cells were cultured in full growth 
medium for 48 hours (CTR), serum free medium for 48 hours (NS 48h) and full growth medium 
containing 20% FCS for 3 (+FGM 3h), 6 (+FGM 6h), 12 (+FGM 12h), 24 (+FGM 24h), 36 (+FGM  
36h) and 48 hours (+FGM 48h) respectively after being transferred back from serum free medium. The 
mRNA level o f  the Bm -3b was normalized to the mRNA level o f  GAPDH in the same sample used. 
The experiment was carried out in the same conditions as the FACS analysis as stated in Figure 3.9. 
The mRNA levels o f  Bm -3b and GAPDH in the ND7 cells were tested by quantitative RT-PCR.
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Figure 3.11 The mRNA level o f  cyclin D1 in the ND7 cells after the cells were cultured in full growth 
medium for 48 hours (CTR), serum free medium for 48 hours (NS 48h) and full growth medium 
containing 20% FCS for 3 (+FGM 3h), 6 (+FGM 6h), 12 (+FGM 12h), 24 (+FGM 24h), 36 (+FGM 
36h) and 48 hours (+FGM 48h) respectively after being transferred back from serum free medium. The 
mRNA level o f  the cyclin D1 was normalized to the mRNA level o f  GAPDH in the same sample used. 
The experiment was carried out in the same conditions as the FACS analysis as stated in Figure 3.9. 
The mRNA levels o f  cyclin D1 and GAPDH in the ND7 cells were tested by quantitative RT-PCR.
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3.3 Benzo(a)pyrene exposure to ND7 cells
Results
Benzo(a)pyrene is an carcinogen found as the environmental pollutant. Exposure to 
benzo(a)pyrene would increase the risk o f tumorgenesis (Davis et al. 2002). Previous 
findings have shown that elevation o f Bm-3b level correlates with changes that would 
contribute to tumorgenesis. Therefore, Benzo(a)pyrene may induce tumorgenesis by 
elevating the Bm-3b in cells. In this experiment, we test the idea of whether 
benzo(a)pyrene could increase Bm-3b in ND7 cells. Therefore, 1X106 o f ND7 cells 
were plated and incubated for 12 hours in full growth medium. After 12 hours, three 
different concentrations o f benzo(a)pyrene were added to the medium— 2.5, 5 and 
10pg/ml. Acetone, which was used as a control as it was used to dissolve 
benzo(a)pyrene, were also added. After the incubation o f different concentrations of 
benzo(a)pyrene and acetone for 12 hours, the cells were harvested for FACS analysis, 
quantitative RT-PCR and western blotting.
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3.3.1 The changes in percentage of ND7 cells in different stages of the cell cycle 
following benzo(a)pyrene exposure
Due to the discrepancy between the data from set one and two, the data were analyzed 
separately. Nevertheless, the results (Table 3.3) showed that both cells subjected to 
addition of acetone and benzo(a)pyrene of different concentrations were arrested in 
the S phase of the cell cycle. This indicated that the cells arrested at the S phase of the 
cell cycle when cultured with benzo(a)pyrene were caused by acetone, which 
dissolved benzo(a)pyrene, rather than benzo(a)pyrene. If benzo(a)pyrene could arrest 
cells in S phase, more cells should have accumulated in the S phase o f the cell cycle 
when the concentrations of benzo(a)pyrene were increased. Hence, the FACS result 
showed that benzo(a)pyrene did not cause cell cycle arrest.
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G1 Phase (%) S phase (%) G2/M phase (%)
Set 1 Set 2 Set 1 Set 2 Set 1 Set 2
Acetone 36.7 12 44.1 77.6 19.2 10.4
Benzo(a)Pyrene(2.5 pg/ml) 38.3 22.9 44.8 77.1 17.1 0
Benzo(a)Pyrene(5 pg/ml) 38.6 7.9 44.8 54.5 18.7 37.6
Benzo(a)Pyrene( 1 Opg/ml) 37.9 29.2 44 70.8 18 0
Table 3.3 The percentage o f  ND7 cells in different phases o f  the cell cycle following exposure to 
benzo(a)pyrene at various concentrations. 1X106 o f  cells were plated in full serum medium and were 
left for 12 hours. Subsequently, benzo(a)pyrene was added for 12 hours. Acetone, which was used as a 
control, was added to the cells for 12 hours. A ll the cells were harvested at the same time for the FACS 
analysis.
3.3.2 The mRNA level of Brn-3b in ND7 cells under Benzo(a)pyrene exposure
In this experiment, whether different concentrations o f benzo(a)pyrene changes the 
mRNA level o f Bm-3b was investigated using quantitative RT-PCR. RNA were 
extracted from the cells cultured in the same condition as the cells for FACS analysis, 
and the RNA were used for cDNA synthesis. By quantitative RT-PCR, the mRNA 
level of Bm-3b was estimated and normalized against GAPDH.
From the results (Figure 3.12), the mRNA level o f Bm-3b failed to correlate with 
different concentrations of benzo(a)pyrene exposure. Among the different
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concentrations, the concentration of 5pg/ml of benzo(a)pyrene seemed to induce an 
increase of mRNA level of Bm-3b, however, the mRNA level o f Bm-3b in the cells 
following this exposure showed a lower mRNA level of Bm-3b than the untreated 
control. Therefore, no conclusive relationship between benzo(a)pyrene and Bm-3b 
could be drawn.
The mRNA level of Brn-3b normalized to GAPDH
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Figure 3.12 The mRNA level o f  Bm-3b in ND7 cells following exposure to benzo(a)pyrene at various 
concentrations. The mRNA level o f  the Bm-3b was normalized to the mRNA level o f  GAPDH in the 
same sample used. The experiment was carried out in the same conditions as the FACS analysis as 
stated in Table 3.4. The mRNA levels o f  Bm-3b and GAPDH in the ND 7 cells were tested by 
quantitative RT-PCR.
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3.4 The experiment on cell cycle arrest of MCF7 cells following various 
treatments
The experiments of cell cycle arrest were carried in parallel with MCF7 cells using 
the same set o f drugs with the same condition. However, from the result of the FACS 
analysis (data not shown), an abnormal high percentage o f cells in G1 phase was 
observed in the untreated control, indicating that the cells were not actively 
proliferating. Also, the results of the FACS analysis of the various treatments showed 
a high discrepancy, and no mRNA levels of Bm-3b, cyclin D1 and cyclin E were 
tested due to the limitation of time, therefore, the results o f this experiment are not 
presented as no clear conclusion can be drawn.
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Chapter Four
Discussion
Bm-3b was firstly identified from ND7 using novel degenerative oligonucleotides 
primers (Lillycrop et al. 1992). Subsequently, it has been found that Bm-3b is 
expressed in regions of the central and peripheral nervous system (Turner et al. 1994), 
and it plays an important role in regulating survival and development of specific 
subset of neurons in the retinal ganglia. Studies using Bm-3b knockout mice showed 
that lack o f Bm-3b caused blindness in the mice because o f a significant loss of 
retinal ganglion cells (Gan et al. 1996). Bm-3b has also been found to be expressed in 
other tissues such as the testis and breast (Budhram-Mahadeo et al. 2001) and has 
been showed to play a role in regulating growth and proliferation of these cells. 
Therefore, expression o f Bm-3b is important for regulating normal cellular functions 
such as growth and proliferation. However, it has been shown that high levels of 
Bm-3b may contribute to uncontrolled proliferation in breast cancer cells and 
neuroblastoma cell lines, and therefore may cause tumorigenesis (Budhram-Mahadeo 
et al. 1999;Dennis et al. 2001;Irshad et al. 2004).
Previous studies have shown that increased expression of Bm-3b enhances
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proliferation in neuroblastoma and breast cancer cells (Irshad et al. 2004;Sonia et al. 
2005). Moreover, it has been found that Bm-3b upregulates CDK4 and cyclin D1 in 
MCF7 breast cancer cell lines. These suggest that Bm-3b controls cell proliferation, at 
least in part, by activating expression o f cell cycle regulators such as cyclin D1 and 
CDK4, which cooperate to drive cell progression from the G1 phase to the S phase of 
the cell cycle. However, whether expression of Bm-3b changed at different phases of 
the cell cycle and when it activates its target gene cyclin D1 remain unclear. Thus, in 
this study, we aim to analyze the changes in mRNA levels o f Bm-3b, cyclin D1 and 
cyclin E under different conditions.
Neuroblastoma ND7 and human breast cancer cell MCF7 were chosen for this study. 
Bm-3b is highly expressed in neuroblastoma cells if  cells are proliferating but 
decreased if cells stop dividing and start differentiating (Latchman 2004). It has been 
observed that neuroblastoma cells that expresses high levels o f Bm-3b proliferate 
more rapidly but also failed to respond to growth inhibitory effect signals such as 
retinoic acid and continued to proliferate in the presence of retinoic acid. Elevation of 
Bm-3b not only increases cell proliferation rate, but also enhances tumour in vivo. 
Increased Bm-3b in neuroblastoma cells have been observed to enhance growth in 
monolayer and under anchorage-independent conditions which is a critical
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characteristic that is required for tumour cells to progress in vitro. A study using in 
vivo xenograft models showed that athymic nude mice with high expression levels of 
Bm-3b resulted in rapid growth o f tumours. Moreover, a significant increase in the 
number of invading cells arising from clones had high Bm-3b expression, indicating 
that elevated Bm-3b expression enhances the invasiveness o f the neuroblastoma cells 
(Irshad et al. 2004). As a transcription factor, Bm-3b changes the growth and 
behaviours of cells by regulating gene expression at the transcriptional level. At the 
molecular level, Bm-3b can repress the promoters o f neuronal genes such as 
a-intemexin (Budhram-Mahadeo et al. 1995) and neurofilament (Smith et al. 1997) 
which are important for neuronal differentiation so that the cells proliferate and fail to 
differentiate under appropriate conditions (Budhram-Mahadeo et al. 1995; Smith et al. 
1997).
The significance o f changing Bm-3b protein level on cellular growth and behaviour is 
further supported by the results o f studies in the breast cancer cell line MCF7. Breast 
cancer cells with increased Bm-3b demonstrated increased anchorage-independent 
growth, invasiveness and resistance to chemotherapeutic drugs (Sonia et al. 2005). It 
appears that these effects are regulated by Bm-3b through its ability to alter 
expression of target genes. Increased Bm-3b upregulates the gene expression of
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various target genes related to cell proliferation such as c-myc (Sonia et al. 2005), 
cyclin D1 (Samady et al. 2004) and estrogen receptor (Dennis et al. 2001). Increasing 
expression o f these target genes are associated with increased proliferation in many 
breast cancers. Also, high level o f Bm-3b elevates the gene expression of HSP27 and 
cathepsin D which have been shown to significantly enhance invasiveness and drug 
resistance o f breast cancers (Sonia et al. 2005). Plakoglobin, which is associated with 
cell adhesion, is downregulated with increased Bm-3b, further supporting the role of 
elevated Bm-3b at enhaning tumourigenesis (Sonia et al. 2005).
In this study, as we aim to understand other mechanism that may cause increased 
proliferation or tumourigenesis triggered by Bm-3b, we set up a model to test whether 
the mRNA level o f Bm-3b in ND7 cells changes in different phases o f the cell cycle.
To do this, the cells were arrested at different phases o f the cell cycle following the 
specified treatments. It was observed that the mRNA level o f Bm-3b in the cells 
increased compared with the control when the cells were arrested in G1 phase of the 
cell cycle, whereas the mRNA level of Bm-3b in the cells decreased compared with 
the control when the cells were arrested in G2/M phase o f  the cell cycle. This result 
suggested that Bm-3b protein may express in a cell cycle dependent manner.
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The mRNA level o f cyclin D1 and cyclin E were also measured in parallel to the level 
of Bm-3b mRNA in the cells following the specified treatments. Interestingly, the 
mRNA levels of cyclin D1 and cyclin E followed a similar trend to the mRNA level of 
Bm-3b in the cells; when the mRNA level of Brn-3b increased, the mRNA levels of 
cyclin D1 and cyclin E increased, and vice versa. These results indicated that Bm-3b, 
as a transcription factor, may regulate the expression of cyclin D1 and cyclin E 
through a direct or indirect pathway.
Having shown that the mRNA level of Bm-3b correlated to that o f cyclin D1 and 
cyclin E when cells were arrested at different phases of the cell cycle following 
specified treatments, a further study to investigate whether the mRNA levels of 
Bm-3b and cyclin D1 change in synchronized cells to allow cells to progress in a 
uniform manner through the cell cycle was undertaken. Cells were synchronized by 
using serum free medium because previous studies have shown that deprivation of 
serum growth factor induces cell cycle arrest while addition of serum back to these 
synchronized cells resume progression through the cell cycle normally 
(Budhram-Mahadeo et al. 1994). The result clearly showed that the mRNA level of 
Bm-3b in the cells correlates to the mRNA level of cyclin D1 in these cells; when 
mRNA level of Bm-3b increased, the mRNA of cyclin D1 increased accordingly, and
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vice versa. This observation, in agreement with the observation made with the cells 
arrested at a specific phase of the cell cycle following specified treatments, further 
confirmed the correlation between mRNA levels of Bm-3b and cyclin D l. This 
positive correlation of changes in the mRNA levels of Bm-3b and cyclin Dl 
suggested that Bm-3b, as a transcription factor, may upregulate the mRNA level of 
cyclin D l. Indeed, Bm-3b has been observed to activate the cyclin D l expression by 
binding to the cyclin D l promoter (Personal communication with Dr. 
Budhram-Mahadeo).
Cyclin D l is crucial in cell cycle progression. It cooperates with CDK4 to allow the 
cell to progress through G1 phase by phosphorylating the retinoblastoma protein (RB). 
This in turn activates the E2F transcription factor and allows expression of genes such 
as cyclin E to drive cell cycle progression (Stacey 2003). Interestingly, overexpression 
o f cyclin D l accelerates the G l/S transitions (Resnitzky et al. 1994). As a result, this 
shortens the length o f G1 phase and has implication to cancer (Eastman 2004).
The G1 phase is important for controlling cell fate. In this phase, cells decide whether 
to prevent cycling when, for example, there is significant DNA damage or lack of 
appropriate signals. This is crucial to prevent damaged DNA from passaging to the
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daughter cells (Eastman 2004;Lewin 2000). The cell will undergo apoptosis if  the 
damage cannot be rescued. Therefore, shortening the G1 phase shortens the time for 
cells to the make decision of either arresting or undergoing apoptosis when necessary. 
Thus, high levels of cyclin Dl is directly related to tumorgenesis (Johnson and Walker 
1999). Indeed, RNA and protein levels of cyclin D l have recently been found to be 
highly expressed in neuroblastomas, indicating its role in tumours (Noesel and 
Versteeg 2004).
Cyclin D l protein overexpression is found in up to 50% o f human breast cancers. 
Interestingly, overexpressed cyclin D l has been shown to bind directly and activate 
the estrogen receptor in CDK and pRB-indpendent fashion. A large majority of cyclin 
Dl-overexpressing breast cancers are ER positive. Cyclin D l directly interacted with 
ER to trigger binding of ER to an estrogen responsive element and increased target 
gene transcription. Moreover, this effect is independent to CDK4 and pRB as cyclin 
D l mutants that cannot bind to CDK4 or pRB can still exert this effect (Arnold and 
Papanikolaou 2005).
In this study, Bm-3b also appeared to regulate expression o f cyclin E. Indeed, it has 
been suggested that high level of cyclin E play an important role in tumorigenesis by
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causing a neuploidy (gains and losses o f one or more chromosomes of a diploid 
genome), which is a form of genetic instability frequently observed in neuroblastoma 
(Noesel and Versteeg 2004). Generally, incorrect segregation of chromatids and 
aneuploidy are considered to result in amplification of centrosomes (Noesel and 
Versteeg 2004). Elevated cyclin E expression can enhance such aberrations of the 
centrosomes, and this leads to chromosomal instability in tumours (Fukasawa et al. 
1996;Mussman et al. 2000).
Previous studies have shown that high level of Bm-3b in cancer cells inhibits 
expression o f tumour suppressor genes such as BRCA-1 (Dennis et al. 2001). In this 
study, along with the unpublished results from communication with Dr. 
Budhram-Mahadeo, it is found that Bm-3b regulates gene expression of cyclin D l. 
Taken together, high level of Bm-3b increases the risk o f tumourigenesis by 
regulating various gene expressions. However, the reason o f the high expression level 
o f Bm-3b remains unclear. Previous studies showed that exposure to carcinogens such 
as benzo(a)pyrene increases the risk for tumourigenesis (Davis et al. 2002). Taking 
this in mind, therefore it is possible that exposure of carcinogen is a factor to increase 
the expression of Bm-3b which in turn cause tumourigenesis.
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In this study, we tested whether different concentrations of benzo(a)pyrene treatment 
would induce an increase of Bm-3b mRNA level in ND7 cells. However, it was found 
that the benzo(a)pyrene did not increase the Bm-3b mRNA level as there was no clear 
relationship between different concentrations of benzo(a)pyrene and changes in the 
level of Bm-3b mRNA.
Further experiments
As overexpression of cyclin D l has been observed in various cancer cell lines, apart 
from the neuroblastoma and breast cancers, such as esophageal, bladder, lung, 
squamous carcinomas (Johnson and Walker 1999), and Bm-3b has also been detected 
to express in various cell types, thus it would be worthy to investigate whether Bm-3b 
upregulates cyclin Dl in other cancers.
Also, based on the finding o f this study, further experiment could be carried out to 
investigate how Bm-3b regulate cyclin Dl at various stages of the cell cycle, for 
example early G l, mid G1 or late G1 phase of the cell cycle. Moreover, as shown in 
this study, mRNA level of Bm-3b also correlates to the mRNA level of cyclin E, 
therefore, further experiment could be carried out to confirm whether Bm-3b could
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also regulate cyclin E or not.
Though it is clear that high level of Bm-3b protein causes tumourigenesis, however, 
the cause it is still unclear. Thus, further experiment can be carried out to investigate 
the cause of such elevation observed in tumours.
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Appendices
Appendix 1: Preparation of 10% FCS in L-15 with P/S
The 50ml of FCS(gold) was filtered by a filter with 45 pm pore size and was added to 
500ml of L-15. 4.3ml o f 35% D-glucose solution was also filtered by a filter with 
45pm pore size and was added to 500ml of L-15. 26.4ml of sodium bicarbonate and 
585pl of L-glutamine were added to the medium. Finally, 5ml o f P/S (100 U/ml 
penicillin and 100 pg/ml streptomycin) were added to medium.
Appendix 2: Preparation of 10% FCS in D-MEM with P/S
FCS was filtered by a filter with 45 pm pore size and 50ml of it was added to 500ml of 
D-MEM to make up 10% FCS in D-MEM. 5ml of P/S (100 U/ml penicillin and 100 
pg/ml streptomycin) were added to medium
Appendix 3: Preparation of serum free medium in L-15 with P/S
The procedures of preparing the serum free medium are same as that of preparing the 
L-15 full growth medium (please refer the appendix 1) except 10ml of filtered 10% 
bovine serum albumin was added instead of the FCS.
Appendix 4: Preparation of PBS
The PBS (Gibco) was prepared by dissolving the PBS tablet 500ml of MilliQ water. It 
should be highly mentioned that the PBS used in the tissue culture was not prepared in 
that way as they needed to be sterile.
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Appendix 5: Preparation of PI buffer
250mg of sodium citrate was added to 250ml of MilliQ water. 250pl of TritonXlOO 
was then added to the mixture.
Appendix 6: Preparation of DEPC
0.5ml of DEPC was added to 500ml of MilliQ water. The mixture was left on at room 
temperature for 2 hours, and was taken to autoclave.
Appendix 7: Preparation of 2X sample buffer
2X sample buffer was prepared by mixing 6g of sodium dodecyl sulphate (SDS), 1.4g 
o f tris(hydroxymethyl)methylamine (Tris) and 20ml o f glycerol to 100ml of MilliQ 
water.
Appendix 8: Preparation of gel running buffer
In order to prepare the gel running buffer, 2g of SDS, 90.9g o f Tris were added to 
300ml of MilliQ water. Finally, MilliQ water was then added to bring the final 
volume to 500ml.
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Appendix 9: Preparation of 10% of APS
10% of APS was prepared by dissolving 20mg of APS powder (Sigma) into 200pi of 
MilliQ water.
Appendix 10: Preparation of gel stacking buffer
In order to prepare the gel running buffer, 2g of sodium dodecyl sulphate (SDS) and 
30.25g of tris(hydroxymethyl)methylamine (Tris) were added to 300ml of MilliQ 
water. Finally, MilliQ water was then added to bring the final volume to 500ml.
Appendix 11: Preparation of running buffer
In order to prepare the running buffer, 30.3g of Tris, 144.2g o f glycine and lOg of 
SDS were added to 600ml of MilliQ water. Finally, MilliQ water was then added to 
bring the final volume to 1000ml.
Appendix 12: Preparation of transfer buffer
In order to prepare the transfer buffer, 30.3g of Tris and 144.2g o f glycine were added 
to 600ml of MilliQ water. Finally, MilliQ water was then added to bring the final 
volume to 1000ml.
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Appendix 13: Preparation of MPT
The MPT was prepared by mixing lOg of non-fat milk powder (Saintsbury) with 
1000ml of PBS and 1ml of Tween-20 (Sigma).
Appendix 14: Preparation of primary antibody
Primary antibody for western blotting was preparing by mixing the primary antibody 
chosen for the experiment with MPT. The volumes o f the antibody and the MPT used 
depend on the ratio required to probe for a specific protein. Normally, the ratio of 
1:1000 was used. To prepare this, 50pl o f the primary antibody was added to 50ml of 
the MPT.
Appendix 15: Preparation of secondary antibody
Secondary antibody for western blotting was preparing by mixing the secondary 
antibody chosen for the experiment with MPT. The volumes of the antibody and the 
MPT used depend on the ratio required to probe for the primary antibody. Normally, 
the ratio of 1:3000 was used. To prepare this, 20p.l of the secondary antibody was 
added to 60ml of the MPT.
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